Journal of Clinical Psychiatry

Subject Index to Volume 59: January 1998 Through December 1998

Academic Highlights
Atypical antipsychotic agents in the treatment of schizophrenia and other psychiatric disorders, part I: unique patient populations. May 259–265
Atypical antipsychotic agents in the treatment of schizophrenia and other psychiatric disorders, part II: special considerations. June 322–328
Discontinuation of antidepressant therapy: emerging complications and their relevance. Oct 541–548
Update on the management of bipolar illness [CME]. Sept 484–495
Acetaminophen
Fulminant hepatic failure from acetaminophen in an anorexic patient treated with carbamazepine [letter]. Young, Nov 622
Acquired Immunodeficiency Syndrome see HIV
ADHD see Attention-Deficit/Hyperactivity Disorder
Adolescents
Psychopharmacology of ADHD: children and adolescents. Findling, Suppl 7, 42–49
Rage attacks in children and adolescents with Tourette's disorder: a pilot study. Budman, Nov 576–580
Special considerations: use of lithium in children, adolescents, and elderly populations. Tueth, Suppl 6, 66–73
Treatment and outcomes in adolescents with schizophrenia. Schulz, Suppl 1, 50–54
Use of atypical neuroleptics in child and adolescent psychiatry. Toren, Dec 644–656
Affective Disorders see Bipolar Disorder; Depression; Mania; Mood; Seasonal Affective Disorder
Aggression see also Violence
Divalproex sodium for impulsive aggressive behavior in patients with personality disorder. Kavoussi, Dec 676–680
AIDS see HIV
Akathisia
Second thoughts about clozapine as a treatment for neuroleptic-induced akathisia [letter]. Levine, Apr 195
Alcohol and Alcoholism
Dawn simulation treatment of abstinent alcoholics with winter depression [CME Article]. Avery, Jan 36–42
Individualized treatment for outpatients withdrawing from alcohol. Wiseman, June 289–293
Allergic Reactions
Clozapine-induced eosinophilia: subsequent neutropenia and corresponding allergic mechanisms [letter]. Lucht, Apr 195–197
Recurrence of lamotrigine-associated rash with rechallenge [letter]. Buzan, Feb 87
Risperidone and allergic reactions [letter]. Terao, Feb 82–83
Alzheimer's Disease
Alzheimer's disease management. Rabins, Suppl 13, 36–38
Assessment of treatment-associated changes in behavior and cholinergic therapy of neuropsychiatric symptoms in Alzheimer's disease. Cummings, Suppl 13, 23–30
Cholinergic deficit in Alzheimer's disease. Whitehouse, Suppl 13, 19–22
Developing treatment guidelines for Alzheimer's disease and other dementias. Rabins, Suppl 11, 17–19
Diagnosis and treatment of depression in patients with Alzheimer's disease and other dementias. Katz, Suppl 9, 38–44
Early diagnosis and management of Alzheimer's disease. Duncan, Suppl 9, 15–21
Early recognition of Alzheimer's disease: what is consensual? what is controversial? what is practical? Doraiswamy, Suppl 13, 6–18
Evaluating response to metrifonate. Tariot, Suppl 9, 33–37
Future therapeutic approaches to Alzheimer's disease. Davis, Suppl 11, 14–16
Introduction. Alzheimer's disease: from research to practice. Schneider, Suppl 11, 3
Introduction: Alzheimer's disease management. Cummings, Suppl 13, 4–5
New cholinergic therapies: treatment tools for the psychiatrist. Tune, Suppl 13, 31–35
Pathogenesis of Alzheimer's disease. Small, Suppl 9, 7–14
Pharmacologic approaches to cognitive deficits in Alzheimer's disease. Peskind, Suppl 9, 22–27
Psychopharmacology of noncognitive abnormal behaviors in Alzheimer's disease. Raskind, Suppl 9, 28–32
Role of the psychiatrist in Alzheimer's disease. Grossberg, Suppl 9, 3–6
Anandamide
Getting stoned without inhaling: anandamide is the brain's natural marijuana [Brainstorms]. Stahl, Nov 566–567
Anger
Depression with anger attacks. Fava, Suppl 18, 18–22
Paroxetine treatment of episodic rages associated with Tourette's disorder. Bruun, Nov 581–584
Rage attacks in children and adolescents with Tourette's disorder: a pilot study. Budman, Nov 576–580
Anorexia Nervosa
Fulminant hepatic failure from acetaminophen in an anorexic patient treated with carbamazepine [letter]. Young, Nov 622
Antiandrogen Treatment
Irradiation therapy prevents gynecomastia in sex offenders treated with antiandrogens [letter]. Eriksson, Aug 432–433
Anticardiolipin Antibodies
High association of anticardiolipin antibodies with psychosis. Schwartz, Jan 20–23
Anticonvulsants
Anticonvulsants and antipsychotics in the treatment of bipolar disorder. Keck, Suppl 6, 74–81
Use of anticonvulsants to augment antidepressant medication. Dietrich, Suppl 5, 51–58
Antidepressants see also specific drugs
Antidepressant augmentation: conclusions and recommendations. Sussman, Suppl 5, 70–73
Antidepressant drugs: disturbing and potentially dangerous adverse effects. Settle, Suppl 16, 25–30
Antidepressant-induced sexual dysfunction. Segraves, Suppl 4, 48–54
Antidepressant response in late-life depression. Roose, Suppl 10, 4–8
Antidepressants in panic disorder: clinical and preclinical mechanisms. Nutt, Suppl 8, 24–28
Anxiolytic antidepressant augmentation. Sussman, Suppl 5, 42–48
Augmentation strategies with serotonergic-noradrenergic combinations. Nelson, Suppl 5, 65–68
Basic psychopharmacology of antidepressants, part 1: antidepressants have seven distinct mechanisms of action. Stahl, Suppl 4, 5–14
Basic psychopharmacology of antidepressants, part 2: estrogen as an adjunct to antidepressant treatment. Stahl, Suppl 4, 15–24
Cardiovascular effects of antidepressant drugs: updated. Glassman, Suppl 15, 13–18
Depression, sleep, and antidepressants. Thase, Suppl 4, 55–65
Differential pharmacology of newer antidepressants. DeVane, Suppl 20, 85–93
Discontinuation of antidepressant therapy: emerging complications and their relevance [Academic Highlights], Oct 541–548
Dopaminergic agents and stimulants as antidepressant augmentation strategies. Nierenberg, Suppl 5, 60–63
Drug and diet interactions: avoiding therapeutic paralysis. Jefferson, Suppl 16, 31–39
Drug interactions with newer antidepressants: role of human cytochromes P450. Greenblatt, Suppl 15, 19–27
Economic outcomes with antidepressant pharmacotherapy: a retrospective intent-to-treat analysis. Sclar, Suppl 2, 13–17
Introduction. Augmentation of antidepressant medication. Sussman, Suppl 5, 3–4
Introduction. Focus on panic disorder: antidepressants in practice. Ballenger, Suppl 8, 3
Lithium augmentation of antidepressants in

treatment-refractory depression. Heit, Suppl 6, 28–33
Loss of antidepressant efficacy during maintenance therapy: possible mechanisms and treatments. Byrne, June 279–288
Monoamine dysfunction and the pathophysiology and treatment of depression. Charney, Suppl 14, 11–14
Noradrenergic versus serotonergic antidepressants: predictors of treatment response. Schatzberg, Suppl 14, 15–18
Pharmacokinetic interactions of antidepressants. Richelson, Suppl 10, 22–26
Pharmacotherapy of panic disorder: differential efficacy from a clinical viewpoint. den Boer, Suppl 8, 30–36
Role of medication in managed care for depression. Glazer, Suppl 2, 67
Selecting an antidepressant by using mechanism of action to enhance efficacy and avoid side effects. Stahl, Suppl 18, 23–29
Side effect burden associated with drug treatment of panic disorder. Baldwin, Suppl 8, 39–44
Treating antidepressant nonresponders with augmentation strategies: an overview. Thase, Suppl 5, 5–12
Treatment of antidepressant nonresponders: augmentation or switch? Nelson, Suppl 15, 35–41
Use of anticonvulsants to augment antidepressant medication. Dietrich, Suppl 5, 51–58
Use of antidepressant drugs in patients with heart disease. Glassman, Suppl 10, 16–21
Use of lithium to augment antidepressant medication. Rouillon, Suppl 5, 32–39
Use of pindolol to potentiate antidepressant medication. Blier, Suppl 5, 16–23
Use of thyroid supplements to augment antidepressant medication. Joffe, Suppl 5, 26–29

Antipsychotics see also specific drugs

Adverse effects of the atypical antipsychotics. Collaborative Working Group, Suppl 12, 17–22
Anticonvulsants and antipsychotics in the treatment of bipolar disorder. Keck, Suppl 6, 74–81
Antipsychotic agents and bipolar disorder. Tohen, Suppl 1, 38–48
Assessing the effects of atypical antipsychotics on negative symptoms. Collaborative Working Group, Suppl 12, 28–34
Atypical antipsychotic agents in the treatment of schizophrenia and other psychiatric disorders, part I: unique patient populations [ACADEMIC HIGHLIGHTS]. May 259–265
Atypical antipsychotic agents in the treatment of schizophrenia and other psychiatric disorders, part II: special considerations [ACADEMIC HIGHLIGHTS]. June 322–328
Atypical antipsychotics for treatment of depression in schizophrenia and affective disorders. Collaborative Working Group, Suppl 12, 41–45
Clinical development of atypical antipsychotics: research design and evaluation. Collaborative Working Group, Suppl 12, 10–16
Common treatment goals of antipsychotics: acute treatment. Sharif, Suppl 19, 5–8
Efficacy and safety of neuroleptics in behavioral disorders associated with dementia [CME ARTICLE]. Lanctôt, Oct 550–561
Evaluating the effects of antipsychotics on cognition in schizophrenia. Collaborative Working Group, Suppl 12, 35–40
Facilitating compliance with antipsychotic medication. Marder, Suppl 3, 21–25
Formulary decisions and health economics. Glazer, Suppl 19, 23–29
Introduction: routine use of atypical antipsychotic agents. Simpson, Suppl 19, 3–4
Long-term considerations after switching antipsychotics. Weiden, Suppl 19, 36–49
Management of chronic psychotic ambulatory outpatients. Petty, Suppl 19, 30–35
Management of the agitated elderly patient in the nursing home: the role of atypical antipsychotics. Verma, Suppl 19, 50–55
Measuring outcome in schizophrenia: differences among the atypical antipsychotics. Collaborative Working Group, Suppl 12, 3–9
Pharmacologic treatment of first-episode schizophrenia: early intervention is key to outcome. DeQuardo, Suppl 19, 9–17
Prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics. Miller CH, Feb 69–75
Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. Hägg, June 294–299
Routine use of atypical antipsychotic agents: maintenance treatment. Kinon, Suppl 19, 18–22
Treatment of special populations with the atypical antipsychotics. Collaborative Working Group, Suppl 12, 46–52
Use of atypical neuroleptics in child and adolescent psychiatry. Toren, Dec 644–656
What makes an antipsychotic atypical? [BRAINSTORMS] Stahl, Aug 403–404

Anxiety see also Social Anxiety Disorder

Anxious depression. Lydiard, Suppl 18, 10–17
Buspirone in the management of anxiety and irritability in children with pervasive developmental disorders: results of an open-label study. Buitelaar, Feb 56–59
Course of mood and anxiety disorders during pregnancy and the postpartum period. Altshuler, Suppl 2, 29–33
Introduction. Depression and anxiety: new tools for diagnosis and treatment. Katon, Suppl 20, 3–4
Medically unexplained symptoms in primary care. Katon, Suppl 20, 15–21
Meta-analysis of eight randomized, double-blind, controlled clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety. Fawcett, Mar 123–127
Should anxiety and insomnia influence antidepressant selection: a randomized comparison of fluoxetine and imipramine. Simon, Feb 49–55

Attention-Deficit/Hyperactivity Disorder

Addressing comorbidity in adults with attention-deficit/hyperactivity disorder. Hornig, Suppl 7, 69–75
ADHD through the life span: the role of bupropion in treatment. Cantwell, Suppl 4, 92–94
Adults with attention-deficit/hyperactivity disorder: a controversial diagnosis. Spencer, Suppl 7, 59–68
Attention-deficit/hyperactivity disorder in males with paraphilias and paraphilia-related disorders: a comorbidity study [CME ARTICLE]. Kafka, July 388–396
Attention-deficit/hyperactivity disorder: a life-span perspective. Biederman, Suppl 7, 4–16
Comorbidity of attention-deficit/hyperactivity disorder with psychiatric disorder: an overview. Pliszka, Suppl 7, 50–58
Diagnosing attention-deficit/hyperactivity disorder in children. Greenhill, Suppl 7, 31–41
Introduction: current issues in attention deficit disorder. Charney, Suppl 7, 3
Methylphenidate treatment for cocaine abusers with adult attention-deficit/hyperactivity disorder: a pilot study. Levin, June 300–305
Neurobiology of attention-deficit/hyperactivity disorder. Zametkin, Suppl 7, 17–23
Pharmacotherapy of attention-deficit/hyperactivity disorder in adults. Wender, Suppl 7, 76–79
Psychopharmacology of ADHD: children and adolescents. Findling, Suppl 7, 42–49
Rating scales in attention-deficit/hyperactivity disorder: use in assessment and treatment monitoring. Conners, Suppl 7, 24–30

Augmentation see Drug Therapy, Combination

Behavioral Disorders

Assessment of treatment-associated changes in behavior and cholinergic therapy of neuropsychiatric symptoms in Alzheimer's disease. Cummings, Suppl 13, 23–30
Efficacy and safety of neuroleptics in behavioral disorders associated with dementia [CME ARTICLE]. Lanctôt, Oct 550–561
Psychopharmacology of noncognitive abnormal behaviors in Alzheimer's disease. Raskind, Suppl 9, 28–32

Behavioral Treatment

Behavioral treatment of chronic insomnia in psychiatrically ill patients [CME ARTICLE]. Dashevsky, Dec 693–699

Benzodiazepines

Pharmacotherapy of panic disorder: differential efficacy from a clinical viewpoint. den Boer, Suppl 8, 30–36
Side effect burden associated with drug treatment of panic disorder. Baldwin, Suppl 8, 39–44

Bipolar Disorder

Anticonvulsants and antipsychotics in the treatment of bipolar disorder. Keck, Suppl 6, 74–81
Antipsychotic agents and bipolar disorder. Tohen, Suppl 1, 38–48
Bipolar depression: specific treatments. Potter, Suppl 18, 30–36
Bipolar disorder: recent issues in diagnosis and classification. Schatzberg, Suppl 6, 5–10
Course of psychiatric and substance abuse syndromes co-occurring with bipolar disorder after a first psychiatric hospitalization. Strakowski, Sept 465–471
Expert consensus guidelines for treating depression in bipolar disorder [Expert Consensus Guideline Series]. Frances, Suppl 4, 73–79
Introduction. Lithium in the treatment of manic-depressive illness: an update. Nemeroff, Suppl 6, 3–4
Key treatment studies of lithium in manic-depressive illness: efficacy and side effects. Bowden, Suppl 6, 13–19
Lithium treatment and risk of suicidal behavior in bipolar disorder patients. Tondo, Aug 405–414
Manual-based group psychotherapy for bipolar disorder: a feasibility study. Bauer, Sept 449–455
Medication compliance among patients with bipolar disorder and substance use disorder. Weiss, Apr 172–174

Rapid efficacy of olanzapine augmentation in nonpsychotic bipolar mixed states [letter]. Ketter, Feb 83–85
Rapid titration of mood stabilizers predicts remission from mixed or pure mania in bipolar patients. Goldberg, Apr 151–158; Correction, June 320
Recurrent mood shifts of premenstrual dysphoric disorder can be mistaken for rapid-cycling bipolar II disorder [letter]. Hendrick, Sept 479–480
Tobacco smoking and bipolar disorder. Gonzalez-Pinto, May 225–228
Update on the management of bipolar illness [CME ACADEMIC HIGHLIGHTS]. Shelton, Sept 484–495
Use of lithium and management of women with bipolar disorder during pregnancy and lactation. Llewellyn, Suppl 6, 57–64

Blood Pressure

Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. Thase, Oct 502–508

Body Dysmorphic Disorder

Comparison study of body dysmorphic disorder and obsessive-compulsive disorder. Phillips, Nov 568–575
Efficacy and safety of fluvoxamine in body dysmorphic disorder. Phillips, Apr 165–171

Books Reviewed

Akiskal HS, Cassano GB (eds): *Dysthymia and the Spectrum of Chronic Depressions*. Alarcon, Oct 539–540
Bellack AS, Mueser KT, Gingerich S, Agresta J: *Social Skills Training for Schizophrenia: A Step-by-Step Guide*. Gold, Aug 435
Bloom FE, Kupfer DJ (eds): *Psychopharmacology: The Fourth Generation of Progress*. Zisook, Apr 201
Ciraulo DA, Shader RI, Greenblatt DJ, Creelman W: *Drug Interactions in Psychiatry, 2nd ed.* Ebert, Aug 434–435
Cooper JR, Bloom FE, Roth RH: *The Biochemical Basis of Neuropharmacology, 7th ed*. Ebert, May 258
Goodnick PJ (ed): *Mania: Clinical and Research Perspectives*. Straumanis, Oct 539
Gutheil TG: *The Psychiatrist as Expert Witness*. Bernet, Mar 135
Gutheil TG: *The Psychiatrist in Court: A Survival Guide*. Bernet, Mar 135
Kranzler HR, Rounsaville BJ (eds): *Dual Diagnosis and Treatment: Substance Abuse and Comorbid Medical and Psychiatric Disorders*. Hubbard, Nov 625
Makover RB: *Treatment Planning for Psychotherapists*. Roback, June 321
Miklowitz DJ, Goldstein MJ: *Bipolar Disorder: A Family-Focused Treatment Approach*. Salomon, Aug 434
Nelson JC (ed): *Geriatric Psychopharmacology*. Kwentus, Nov 625–626
Pies RW: *Handbook of Essential Psychopharmacology*. Rubin, Dec 691
Putnam FW: *Dissociation in Children and Adolescents: A Developmental Perspective*. Nurcombe, Dec 691
Stahl SM: *Essential Psychopharmacology: Neuroscientific Basis and Practical Applications*. Ebert, May 258
Steiner H (ed): *Treating Preschool Children*. Brooks, Sept 482
Steiner H (ed): *Treating School-Age Children*. Brooks, Sept 482
Tsuang MT, Faraone SV: *Schizophrenia: The Facts, Second Edition*. Gold, July 385–386
Wettstein RM (ed): *Treatment of Offenders With Mental Disorders*. Bernet, Nov 626

Borderline Personality Disorder

Borderline personality symptomatology, experience of multiple types of trauma, and health care utilization among women in a primary care setting. Sansone, Mar 108–111
Clinical outcome of psychopharmacologic treatment of borderline and schizotypal personality disordered subjects. Coccaro, Suppl 1, 30–35
Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder. Benedetti, Mar 103–107

Brain

Brain mechanisms of social anxiety disorder. Nutt, Suppl 17, 4–9
Brain serotonin neurotransmission: an overview and update with an emphasis on serotonin subsystem heterogeneity, multiple receptors, interactions with other neurotransmitter systems, and consequent implications for understanding the actions of serotonergic drugs. Murphy, Suppl 15, 4–12

Brain Imaging

Neuroimaging for diagnosis of dementia. Small, Suppl 11, 4–7

BRAINSTORMS

Brain fumes: yes, we have NO brain gas. Stahl, Jan 6–7
Brain tonics for brain sprouts: how neurotrophic factors fertilize neurons. Stahl, Apr 149–150
Getting stoned without inhaling: anandamide is the brain's natural marijuana. Stahl, Nov 566–567
How psychiatrists can build new therapies for impotence. Stahl, Feb 47–48
How to appease the appetite of psychotropic drugs. Stahl, Oct 500–501
Neuropharmacology of obesity: my receptors made me eat it. Stahl, Sept 447–448
Nitric oxide physiology and pharmacology. Stahl, Mar 101–102
Not so selective serotonin reuptake inhibitors. Stahl, July 343–344
Recognition molecules are trailblazers for axon pathways. Stahl, May 215–216
Using secondary binding properties to select a not so selective serotonin reuptake inhibitor. Stahl, Dec 642–643
What makes an antipsychotic atypical? Stahl, Aug 403–404
When neurotrophic factors get on your nerves: therapy for neurodegenerative disorders. Stahl, June 277–278

Bruxism

Can bruxism respond to serotonin reuptake inhibitors? [letter] Stein, Mar 133

Bupropion

ADHD through the life span: the role of bupropion in treatment. Cantwell, Suppl 4, 92–94
Bupropion as an antidote for serotonin reuptake inhibitor–induced sexual dysfunction. Ashton, Mar 112–115
Bupropion sustained release and smoking cessation. Goldstein, Suppl 4, 66–72
Bupropion sustained release: a therapeutic overview. Davidson JRT, Suppl 4, 25–31
Bupropion sustained release: side effect profile. Settle, Suppl 4, 32–36
Prospective safety surveillance study for bupropion sustained-release in the treatment of depression. Dunner, July 366–373

Buspirone

Buspirone and imipramine for the treatment of major depression in the elderly. Schweizer, Apr 175–183
Buspirone in the management of anxiety and irritability in children with pervasive developmental disorders: results of an open-label study. Buitelaar, Feb 56–59
Randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression. Landén, Dec 664–668

Carbamazepine

Fulminant hepatic failure from acetaminophen in an anorexic patient treated with carbamazepine [letter]. Young, Nov 622
Risperidone-carbamazepine interactions: is cytochrome P450 3A involved? [letter] Lane; de Leon reply, Aug 430–431

Cardiovascular Effects

Cardiovascular effects of antidepressant drugs: updated. Glassman, Suppl 15, 13–18

Children

Buspirone in the management of anxiety and irritability in children with pervasive developmental disorders: results of an open-label study. Buitelaar, Feb 56–59
Diagnosing attention-deficit/hyperactivity disorder in children. Greenhill, Suppl 7, 31–41
Naturalistic course of pharmacologic treatment of children with maniclike symptoms: a systematic chart review [CME ARTICLE]. Biederman, Nov 628–637
Psychopharmacology of ADHD: children and adolescents. Findling, Suppl 7, 42–49
Rage attacks in children and adolescents with Tourette's disorder: a pilot study. Budman, Nov 576–580
Special considerations: use of lithium in children, adolescents, and elderly populations. Tueth, Suppl 6, 66–73
Use of atypical neuroleptics in child and adolescent psychiatry. Toren, Dec 644–656

Cholinergic Therapy

Assessment of treatment-associated changes in behavior and cholinergic therapy of neuropsychiatric symptoms in Alzheimer's disease. Cummings, Suppl 13, 23–30
Cholinergic deficit in Alzheimer's disease. Whitehouse, Suppl 13, 19–22
New cholinergic therapies: treatment tools for the psychiatrist. Tune, Suppl 13, 31–35

Citalopram

Controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder. Lepola, Oct 528–534

Clomipramine

Attacks of jealousy that responded to clomipramine [letter]. Lawrie, June 317–318
Serotonin syndrome caused by a clomipramine-moclobemide interaction [letter]. Dardennes, July 382–383

Clonidine

Treatment of Tourette's syndrome: multimodal, developmental intervention. Peterson, Suppl 1, 62–74; Correction [letter]. Holmes; Peterson reply, Nov 620

Clozapine

Absence of changes in antidiuretic hormone, angiotensin II, and atrial natriuretic peptide with clozapine treatment of polydipsia-hyponatremia:

2 case reports. Verghese, Aug 415–419
Clinical and neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenic patients: a prospective study. Lindenmayer, Oct 521–527
Clozapine-induced eosinophilia: subsequent neutropenia and corresponding allergic mechanisms [letter]. Lucht, Apr 195–197
Clozapine reduces violence and persistent aggression in schizophrenia. Glazer, Suppl 3, 8–14
Clozapine withdrawal–emergent dystonias and dyskinesias: a case series. Ahmed, Sept 472–477
Effects of clozapine therapy in schizophrenic individuals at risk for tardive dyskinesia. Casey, Suppl 3, 31–37
Elevated plasma clozapine concentrations after phenobarbital discontinuation [letter]. Lane, Mar 131–133
Gastroesophageal reflux as a possible result of clozapine treatment [letter]. Baker, May 257
Leukopenia associated with addition of paroxetine to clozapine [letter]. George, Jan 31
Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder. Benedetti, Mar 103–107
Maximizing clozapine therapy: managing side effects. Lieberman, Suppl 3, 38–43
Optimizing treatment with clozapine. Conley, Suppl 3, 44–48
Prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics. Miller CH, Feb 69–75
Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. Hägg, June 294–299
Psychiatric hospital utilization in patients treated with clozapine for up to 4.5 years in a state mental health care system. Reid, Apr 189–194
Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. Honigfeld, Suppl 3, 3–7
Relation of serum anticholinergicity to cognitive status in schizophrenia patients taking clozapine or risperidone. Tracy, Apr 184–188
Second thoughts about clozapine as a treatment for neuroleptic-induced akathisia [letter]. Levine, Apr 195
Suicide in schizophrenia: risk factors and clozapine treatment. Meltzer, Suppl 3, 15–20
Switching from clozapine to olanzapine in treatment-refractory schizophrenia: safety, clinical efficacy, and predictors of response. Henderson, Nov 585–588

Clozaril National Registry

Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. Honigfeld, Suppl 3, 3–7

Cocaine

Cocaine as a risk factor for neuroleptic-induced acute dystonia. van Harten, Mar 128–130
Methylphenidate treatment for cocaine abusers with adult attention-deficit/hyperactivity disorder: a pilot study. Levin, June 300–305

Cognition

Evaluating the effects of antipsychotics on cognition in schizophrenia. Collaborative Working Group, Suppl 12, 35–40
New therapeutic approaches to cognitive impairment. Schneider, Suppl 11, 8–13
Pharmacologic approaches to cognitive deficits in Alzheimer's disease. Peskind, Suppl 9, 22–27
Relation of serum anticholinergicity to cognitive status in schizophrenia patients taking clozapine or risperidone. Tracy, Apr 184–188

Cognitive-Behavioral Therapy

Cognitive-behavioral group therapy for panic disorder in the general clinical setting: a naturalistic study with 1-year follow-up [CME ARTICLE]. Martinsen, Aug 437–442
Psychotherapy in the overall management strategy for social anxiety disorder. Shear, Suppl 17, 39–44

Comorbidity

Addressing comorbidity in adults with attention-deficit/ hyperactivity disorder. Hornig, Suppl 7, 69–75
Comorbidity in social anxiety disorder: impact on disease burden and management. Lecrubier, Suppl 17, 33–37
Comorbidity of attention-deficit/hyperactivity disorder with psychiatric disorder: an overview. Pliszka, Suppl 7, 50–58
Impact of comorbidity on the treatment of panic disorder. Lecrubier, Suppl 8, 11–14
Occurrence and clinical correlates of psychiatric comorbidity in patients with psychotic disorders. Cassano, Feb 60–68
Treatment of special populations with the atypical antipsychotics. Collaborative Working Group, Suppl 12, 46–52

Compliance

Facilitating compliance with antipsychotic medication. Marder, Suppl 3, 21–25
Medication compliance among patients with bipolar disorder and substance use disorder. Weiss, Apr 172–174

Computers

Computer interviews for depression management. Greist, Suppl 16, 20–24
Self-administered psychotherapy for depression using a telephone-accessed computer system plus booklets: an open U.S.-U.K. study. Osgood-Hynes, July 358–365

Consensus Statements

Consensus guidelines in the treatment of major depressive disorder. Rush, Suppl 20, 73–84
Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety. Ballenger, Suppl 8, 47–54
Consensus statement on social anxiety disorder from the International Consensus Group on Depression and Anxiety. Ballenger, Suppl 17, 54–60
Developing treatment guidelines for Alzheimer's disease and other dementias. Rabins, Suppl 11, 17–19
Expert consensus guidelines for treating depression in bipolar disorder [Expert Consensus Guideline Series]. Frances, Suppl 4, 73–79

Continuing Medical Education (CME)

Attention-deficit/hyperactivity disorder in males with paraphilias and paraphilia-related disorders: a comorbidity study. Kafka, July 388–396
Augmentation of Antidepressant Medication, Suppl 5, 1–76
Behavioral treatment of chronic insomnia in psychiatrically ill patients. Dashevsky, Dec 693–699
Clinical Trial Evaluations and Outcome Measures in Psychiatry, Suppl 12, 1–55
Cognitive-behavioral group therapy for panic disorder in the general clinical setting: a naturalisitic study with 1-year follow-up. Martinsen, Aug 437–442
Current Issues in Attention Deficit Disorder, Suppl 7, 1–82
Dawn simulation treatment of abstinent alcoholics with winter depression. Avery, Jan 36–42
Depression and Anxiety: New Tools for Diagnosis and Treatment, Suppl 20, 1–103
Differences in self-reported sleep complaints in elderly persons living in the community who do or do not take sleep medication. Englert, Mar 137–144
DSM-IV intermittent explosive disorder: a report of 27 cases. McElroy, Apr 203–210
Efficacy and safety of neuroleptics in behavioral disorders associated with dementia. Lanctôt, Oct 550–561
Hoarding: a symptom, not a syndrome. Damecour, May 267–272
How do clinicians respond to patients who miss appointments? Smoller, June 330–338
Naturalistic course of pharmacologic treatment of children with maniclike symptoms: a systematic chart review. Biederman, Nov 628–637
Routine Use of Atypical Antipsychotic Agents, Suppl 19, 1–58
Treatment algorithm use to optimize management of symptomatic patients with a history of mania. Suppes, Feb 89–96
Update on the management of bipolar illness [CME ACADEMIC HIGHLIGHTS]. Sept 484–495

Corrections

Brain structure and function and the outcomes of treatment for depression. Leuchter, 1997 Suppl 16, 22–31; Correction, Jan 32
Effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. Marder, 1997 Dec 538–546; Corrections, Apr 200
Rapid titration of mood stabilizers predicts remission from mixed or pure mania in bipolar patients. Goldberg, Apr 151–158; Correction, June 320
Treatment of Tourette's syndrome: multimodal, developmental intervention. Peterson, Suppl 1, 62–74; Correction [letter]. Holmes; Peterson reply, Nov 620

Costs of Medical Care

Costs of depression: direct and indirect; treatment versus nontreatment. Panzarino, Suppl 20, 11–14
Economic outcomes with antidepressant pharmacotherapy: a retrospective intent-to-treat analysis. Sclar, Suppl 2, 13–17
Formulary decisions and health economics. Glazer, Suppl 19, 23–29
Managed care versus managed money. Glazer, Suppl 2, 62–66

Cytochrome P450

Drug interactions with newer antidepressants: role of human cytochromes P450. Greenblatt, Suppl 15, 19–27
Risperidone-carbamazepine interactions: is cytochrome P450 3A involved? [letter] Lane; de Leon reply, Aug 430–431

Dementia

Clinical interface of depression and dementia. Raskind, Suppl 10, 9–12

Developing treatment guidelines for Alzheimer's disease and other dementias. Rabins, Suppl 11, 17–19
Diagnosis and treatment of depression in patients with Alzheimer's disease and other dementias. Katz, Suppl 9, 38–44
Efficacy and safety of neuroleptics in behavioral disorders associated with dementia [CME Article]. Lanctôt, Oct 550–561
Future therapeutic approaches to Alzheimer's disease. Davis, Suppl 11, 14–16
Neuroimaging for diagnosis of dementia. Small, Suppl 11, 4–7
New therapeutic approaches to cognitive impairment. Schneider, Suppl 11, 8–13

Depression

American health care systems and depression: the past, present, and the future. Hirschfeld, Suppl 20, 5–10
Antidepressant efficacy and tolerability of the selective norepinephrine reuptake inhibitor reboxetine: a review. Burrows, Suppl 14, 4–7
Antidepressant response in late-life depression. Roose, Suppl 10, 4–8
Anxious depression. Lydiard, Suppl 18, 10–17
Atypical antipsychotics for treatment of depression in schizophrenia and affective disorders. Collaborative Working Group, Suppl 12, 41–45
Bipolar depression and antidepressant-induced mania: a naturalistic study. Boerlin, July 374–379
Bipolar depression associated with fenfluramine and phentermine [letter]. Zimmer, July 383–384
Buspirone and imipramine for the treatment of major depression in the elderly. Schweizer, Apr 175–183
Can depression be managed appropriately in primary care? Simon, Suppl 2, 3–8
Chairman's overview: the place of reboxetine in antidepressant therapy. Montgomery, Suppl 14, 26–29
Clinical interface of depression and dementia. Raskind, Suppl 10, 9–12
Comparison of 2 treatment strategies for depressed inpatients: imipramine and lithium addition or mirtazapine and lithium addition. Bruijn, Dec 657–663
Computer interviews for depression management. Greist, Suppl 16, 20–24
Conclusion. Depression and its subtypes: a treatment update. Rosenbaum, Suppl 18, 37–38
Consensus guidelines in the treatment of major depressive disorder. Rush, Suppl 20, 73–84
Costs of depression: direct and indirect; treatment versus nontreatment. Panzarino, Suppl 20, 11–14
Course and treatment of atypical depression. Nierenberg, Suppl 18, 5–9
Depression in the family physician's office: what the psychiatrist needs to know: the Michigan Depression Project. Schwenk, Suppl 20, 94–100
Depression, sleep, and antidepressants. Thase, Suppl 4, 55–65
Depression subtyping: treatment implications. Clayton, Suppl 16, 5–12
Depression with anger attacks. Fava, Suppl 18, 18–22
Diagnosis and treatment of depression in late life. Zisook, Suppl 4, 80–91
Diagnosis and treatment of depression in patients with Alzheimer's disease and other dementias. Katz, Suppl 9, 38–44
Dose-response efficacy of paroxetine in preventing depressive recurrences: a randomized, double-blind study. Franchini, May 229–232
Double-blind, placebo-controlled trial of nefazodone in the treatment of patients hospitalized for major depression. Feighner, May 246–253
Expert consensus guidelines for treating depression in bipolar disorder [Expert Consensus Guideline Series]. Frances, Suppl 4, 73–79
Introduction. Depression and anxiety: new tools for diagnosis and treatment. Katon, Suppl 20, 3–4
Introduction. Depression and its subtypes: a treatment update. Rosenbaum, Suppl 18, 3–4
Introduction. Depressive disorders: advances in clinical management. Jefferson, Suppl 16, 3–4
Introduction: late-life depression. Roose, Suppl 10, 3
Introduction. Reboxetine: a new selective antidepressant for the treatment of depression. Montgomery, Suppl 14, 3
Large open-label study of venlafaxine in depressed outpatients by community-based physicians. Joffe, Oct 515–520
Lithium augmentation of antidepressants in treatment-refractory depression. Heit, Suppl 6, 28–33
Measurement of retardation in depression. Dantchev, Suppl 14, 19–25
Medically unexplained symptoms in primary care. Katon, Suppl 20, 15–21
Meta-analysis of eight randomized, double-blind, controlled clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety. Fawcett, Mar 123–127
Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Wheatley, June 306–312
Monoamine dysfunction and the pathophysiology and treatment of depression. Charney, Suppl 14, 11–14
Noradrenergic versus serotonergic antidepressants: predictors of treatment response. Schatzberg, Suppl 14, 15–18
Once- versus twice-daily venlafaxine therapy in major depression: a randomized, double-blind study. Amsterdam, May 236–240
Overcoming treatment resistance in depression. Nelson, Suppl 16, 13–19
Predictors of response to acute treatment of chronic and double depression with sertraline or imipramine. Hirschfeld, Dec 669–675
Prospective safety surveillance study for bupropion sustained-release in the treatment of depression. Dunner, July 366–373
Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression. Costa e Silva, July 352–357
Randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression. Landén, Dec 664–668
Randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. Rudolph, Mar 116–122
Reboxetine versus fluoxetine: an overview of efficacy and tolerability. Massana, Suppl 14, 8–10
Rectal antidepressant medication in the treatment of depression [letter]. Mirassou, Jan 29
Risperidone monotherapy for psychotic depression unresponsive to other treatments [letter]. Lane, Nov 624
Role of medication in managed care for depression. Glazer, Suppl 2, 67
Self-administered psychotherapy for depression using a telephone-accessed computer system plus booklets: an open U.S.-U.K. study. Osgood-Hynes, July 358–365
Treatment of chronic depression, part 1: study design and rationale for evaluating the comparative efficacy of sertraline and imipramine as acute, crossover, continuation, and maintenance phase therapies. Rush, Nov 589–597
Treatment of chronic depression, part 2: a double-blind, randomized trial of sertraline and imipramine. Keller, Nov 598–607
Treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine. Miller IW, Nov 608–619
Treatment of major depression in HIV-seropositive men. Zisook, May 217–224
Treatment of psychotic depression. Coryell, Suppl 1, 22–27

Developmental Disorders

Buspirone in the management of anxiety and irritability in children with pervasive developmental disorders: results of an open-label study. Buitelaar, Feb 56–59

Diabetes

Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. Hägg, June 294–299

Diagnosis and Classification

Adults with attention-deficit/hyperactivity disorder: a controversial diagnosis. Spencer, Suppl 7, 59–68
Bipolar disorder: recent issues in diagnosis and classification. Schatzberg, Suppl 6, 5–10
Characteristics of 34 adults with psychogenic excoriation. Arnold, Oct 509–514
Diagnosing attention-deficit/hyperactivity disorder in children. Greenhill, Suppl 7, 31–41

Diet and Dieting

Delirium with manic symptoms induced by diet pills [letter]. Bagri, Feb 83
Drug and diet interactions: avoiding therapeutic paralysis. Jefferson, Suppl 16, 31–39

Differential Diagnosis

Early diagnosis and management of Alzheimer's disease. Duncan, Suppl 9, 15–21
Early recognition of Alzheimer's disease: what is consensual? what is controversial? what is practical? Doraiswamy, Suppl 13, 6–18
Recurrent mood shifts of premenstrual dysphoric disorder can be mistaken for rapid-cycling bipolar II disorder [letter]. Hendrick, Sept 479–480

Disulfiram

Disulfiram use in patients with abnormal liver function test results. Saxon, June 313–316

Divalproex Sodium

Divalproex sodium for impulsive aggressive behavior in patients with personality disorder. Kavoussi, Dec 676–680

Dopamine

Dopaminergic agents and stimulants as antidepres-

sant augmentation strategies. Nierenberg, Suppl 5, 60–63
Drug Administration
Rectal antidepressant medication in the treatment of depression [letter]. Mirassou, Jan 29
Ups and downs of oral lithium dosing. Kilts, Suppl 6, 21–26
Drug Discontinuation
Discontinuation of antidepressant therapy: emerging complications and their relevance [ACADEMIC HIGHLIGHTS]. Oct 541–548
Discontinuation symptoms and SSRIs [letter]. Pollack; Schatzberg reply, Oct 535–536
Elevated plasma clozapine concentrations after phenobarbital discontinuation [letter]. Lane, Mar 131–133
FINISH: remembering the discontinuation syndrome [letter]. Berber, May 255
Lithium carbonate: maintenance studies and consequences of withdrawal. Dunner, Suppl 6, 48–55
Manic and psychotic symptoms following risperidone withdrawal in a schizophrenic patient [letter]. Lane, Nov 620–621
Overcoming treatment resistance in depression. Nelson, Suppl 16, 13–19
Problems with switching rapidly from one MAOI to another [letter]. Jefferson, Feb 87
Rebound psychiatric and physical symptoms after gabapentin discontinuation [letter]. Corá-Locatelli, Mar 131
Stroke resulting from a rapid switch from phenelzine to tranylcypromine [letter]. Mattes, July 382
Treatment of antidepressant nonresponders: augmentation or switch? Nelson, Suppl 15, 35–41
Treatment of disequilibrium and nausea in the SRI discontinuation syndrome [letter]. Schechter, Aug 431–432
Treatment of venlafaxine discontinuation symptoms with ondansetron [letter]. Raby, Nov 621–622
Drug Interaction
Drug and diet interactions: avoiding therapeutic paralysis. Jefferson, Suppl 16, 31–39
Drug interactions—friend or foe? Jefferson, Suppl 4, 37–47
Drug interactions with newer antidepressants: role of human cytochromes P450. Greenblatt, Suppl 15, 19–27
Fulminant hepatic failure from acetaminophen in an anorexic patient treated with carbamazepine [letter]. Young, Nov 622
Risperidone-carbamazepine interactions: is cytochrome P450 3A involved? [letter] Lane; de Leon reply, Aug 430–431
Serotonin syndrome caused by a clomipramine-moclobemide interaction [letter]. Dardennes, July 382–383
Drug Therapy, Combination
Antidepressant augmentation: conclusions and recommendations. Sussman, Suppl 5, 70–73
Anxiolytic antidepressant augmentation. Sussman, Suppl 5, 42–48
Augmentation strategies with serotonergic-noradrenergic combinations. Nelson, Suppl 5, 65–68
Comparison of 2 treatment strategies for depressed inpatients: imipramine and lithium addition or mirtazapine and lithium addition. Bruijn, Dec 657–663
Dopaminergic agents and stimulants as antidepressant augmentation strategies. Nierenberg, Suppl 5, 60–63
Introduction: augmentation of antidepressant medication. Sussman, Suppl 5, 3–4
Lithium augmentation of antidepressants in treatment-refractory depression. Heit, Suppl 6, 28–33
Overcoming treatment resistance in depression. Nelson, Suppl 16, 13–19
Treating antidepressant nonresponders with augmentation strategies: an overview. Thase, Suppl 5, 5–12
Treatment of antidepressant nonresponders: augmentation or switch? Nelson, Suppl 15, 35–41
Use of anticonvulsants to augment antidepressant medication. Dietrich, Suppl 5, 51–58
Use of lithium to augment antidepressant medication. Rouillon, Suppl 5, 32–39
Use of pindolol to potentiate antidepressant medication. Blier, Suppl 5, 16–23
Use of thyroid supplements to augment antidepressant medication. Joffe, Suppl 5, 26–29
Dysthymia
Geriatric dysthymia. Kocsis, Suppl 10, 13–15
Dystonia
Acute dystonia with olanzapine [letter]. Landry, July 384
Clozapine withdrawal–emergent dystonias and dyskinesias: a case series. Ahmed, Sept 472–477
Cocaine as a risk factor for neuroleptic-induced acute dystonia. van Harten, Mar 128–130
Eating Disorders see also Anorexia Nervosa
Clinical and polysomnographic features of sleep-related eating disorder. Winkelman, Jan 14–19
Use of selective serotonin reuptake inhibitors in eating disorders. Mayer, Suppl 15, 28–34
Economic Issues see Costs of Medical Care
Elderly
Antidepressant response in late-life depression. Roose, Suppl 10, 4–8
Buspirone and imipramine for the treatment of major depression in the elderly. Schweizer, Apr 175–183
Clinical interface of depression and dementia. Raskind, Suppl 10, 9–12
Diagnosis and treatment of depression in late life. Zisook, Suppl 4, 80–91
Differences in self-reported sleep complaints in elderly persons living in the community who do or do not take sleep medication [CME ARTICLE]. Englert, Mar 137–144
Geriatric dysthymia. Kocsis, Suppl 10, 13–15
Introduction: late-life depression. Roose, Suppl 10, 3
Management of the agitated elderly patient in the nursing home: the role of the atypical antipsychotics. Verma, Suppl 19, 50–55
Pharmacokinetic interactions of antidepressants. Richelson, Suppl 10, 22–26
Seizure during risperidone treatment in an elderly woman treated with concomitant medications [letter]. Lane, Feb 81–82
Special considerations: use of lithium in children, adolescents, and elderly populations. Tueth, Suppl 6, 66–73
Treatment of psychosis in late life. Zayas, Suppl 1, 5–10
Treatment of special populations with the atypical antipsychotics. Collaborative Working Group, Suppl 12, 46–52
Electroconvulsive Therapy
ECT in Texas: 19 months of mandatory reporting. Reid, Jan 8–13
Emergency Treatment
Emergency treatment of acute psychosis. Hillard, Suppl 1, 57–60
Eosinophilia
Clozapine-induced eosinophilia: subsequent neutropenia and corresponding allergic mechanisms [letter]. Lucht, Apr 195–197
Epilepsy
Nefazodone for mood disorder associated with epilepsy [letter]. Balon, Dec 690
Estrogen
Basic psychopharmacology of antidepressants, part 2: estrogen as an adjunct to antidepressant treatment. Stahl, Suppl 4, 15–24
Excoriation
Characteristics of 34 adults with psychogenic excoriation. Arnold, Oct 509–514
Expert Consensus Guideline Series
Expert consensus guidelines for treating depression in bipolar disorder. Frances, Suppl 4, 73–79
Extrapyramidal Side Effects
Article commended [letter]. Lauterbach, Mar 133
Assessment of EPS and tardive dyskinesia in clinical trials. Collaborative Working Group, Suppl 12, 23–27
Prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics. Miller CH, Feb 69–75
Family History
Family history and early psychotogenic response to marijuana [letter]. Bowers, Apr 198–199
Fenfluramine
Bipolar depression associated with fenfluramine and phentermine [letter]. Zimmer, July 383–384
Fluoxetine
Fluoxetine-induced genital anesthesia relieved by *Ginkgo biloba* extract [letter]. Ellison, Apr 199–200
Gabapentin augmentation for fluoxetine-treated patients with obsessive-compulsive disorder [letter]. Corá-Locatelli, Sept 480–481
Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Wheatley, June 306–312
Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression. Costa e Silva, July 352–357
Reboxetine versus fluoxetine: an overview of efficacy and tolerability. Massana, Suppl 14, 8–10
Risperidone may worsen fluoxetine-treated OCD [letter]. Andrade; Saxena reply, May 255–256
Should anxiety and insomnia influence antidepressant selection: a randomized comparison of fluoxetine and imipramine. Simon, Feb 49–55
Fluvoxamine
Efficacy and safety of fluvoxamine in body dysmorphic disorder. Phillips, Apr 165–171
Gabapentin
Gabapentin augmentation for fluoxetine-treated patients with obsessive-compulsive disorder [letter]. Corá-Locatelli, Sept 480–481
Gabapentin treatment of mood disorders: a preliminary study. Ghaemi, Aug 426–429
Rebound psychiatric and physical symptoms after gabapentin discontinuation [letter]. Corá-

Locatelli, Mar 131
Gastroesophageal Reflux
Gastroesophageal reflux as a possible result of clozapine treatment [letter]. Baker, May 257
Genital Anesthesia
Fluoxetine-induced genital anesthesia relieved by *Ginkgo biloba* extract [letter]. Ellison, Apr 199–200
Geriatric Psychiatry see Elderly
***Ginkgo biloba* Extract**
Fluoxetine-induced genital anesthesia relieved by *Ginkgo biloba* extract [letter]. Ellison, Apr 199–200
Grief
Post hoc comparison of paroxetine and nortriptyline for symptoms of traumatic grief. Zygmont, May 241–245
Gynecomastia
Irradiation therapy prevents gynecomastia in sex offenders treated with antiandrogens [letter]. Eriksson, Aug 432–433
Heart Disease
Use of antidepressant drugs in patients with heart disease. Glassman, Suppl 10, 16–21
Hepatic Failure
Fulminant hepatic failure from acetaminophen in an anorexic patient treated with carbamazepine [letter]. Young, Nov 622
HIV
Possible risks associated with valproate treatment of AIDS-related mania [letter]. Jefferson, June 317
Treatment of major depression in HIV-seropositive men. Zisook, May 217–224
Hoarding
Hoarding and treatment response in 38 nondepressed subjects with obsessive-compulsive disorder. Black, Aug 420–425
Hoarding: a symptom, not a syndrome [CME Article]. Damecour, May 267–272
Human Immunodeficiency Virus see HIV
Hyperglycemia
Hyperglycemia associated with olanzapine [letter]. Fertig, Dec 687–689
Hypomania
Hypomania associated with mirtazapine augmentation of sertraline [letter]. Soutullo, June 320
St. John's wort and hypomania [letter]. Schneck, Dec 689
Hyponatremia
Absence of changes in antidiuretic hormone, angiotensin II, and atrial natriuretic peptide with clozapine treatment of polydipsia-hyponatremia: 2 case reports. Verghese, Aug 415–419
Imipramine
Buspirone and imipramine for the treatment of major depression in the elderly. Schweizer, Apr 175–183
Comparison of 2 treatment strategies for depressed inpatients: imipramine and lithium addition or mirtazapine and lithium addition. Bruijn, Dec 657–663
Predictors of response to acute treatment of chronic and double depression with sertraline or imipramine. Hirschfeld, Dec 669–675
Should anxiety and insomnia influence antidepressant selection: a randomized comparison of fluoxetine and imipramine. Simon, Feb 49–55
Treatment of chronic depression, part 1: study design and rationale for evaluating the comparative efficacy of sertraline and imipramine as acute, crossover, continuation, and maintenance phase therapies. Rush, Nov 589–597
Treatment of chronic depression, part 2: a double-blind, randomized trial of sertraline and imipramine. Keller, Nov 598–607
Treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine. Miller IW, Nov 608–619
Impulse-Control Disorders
Opioid antagonists in the treatment of impulse-control disorders. Kim, Apr 159–164
Infants
Impact of maternal psychiatric illness on infant development. Weinberg, Suppl 2, 53–61
Insomnia
Behavioral treatment of chronic insomnia in psychiatrically ill patients [CME Article]. Dashevsky, Dec 693–699
Should anxiety and insomnia influence antidepressant selection: a randomized comparison of fluoxetine and imipramine. Simon, Feb 49–55
Intermittent Explosive Disorder
DSM-IV intermittent explosive disorder: a report of 27 cases [CME Article]. McElroy, Apr 203–210
Irradiation Therapy
Irradiation therapy prevents gynecomastia in sex offenders treated with antiandrogens [letter]. Eriksson, Aug 432–433
Jealousy
Attacks of jealousy that responded to clomipramine [letter]. Lawrie, June 317–318
Journal of Clinical Psychiatry
Apologies and thanks to reviewers [letter]. Gelenberg, Apr 195
Hats off to the reviewers! [editorial] Gelenberg, Jan 3–5
Koro
Emergence of koro after abrupt cessation of olanzapine [letter]. Ramos, Feb 86–87
Lactation
Psychotropic medications in lactation. Llewellyn, Suppl 2, 41–52
Use of lithium and management of women with bipolar disorder during pregnancy and lactation. Llewellyn, Suppl 6, 57–64
Lamotrigine
Recurrence of lamotrigine-associated rash with rechallenge [letter]. Buzan, Feb 87
Leukopenia
Leukopenia associated with addition of paroxetine to clozapine [letter]. George, Jan 31
Light Therapy see Phototherapy
Lithium
Commentary. Contemporary use of lithium. Kalin, Suppl 6, 35–36
Comparison of 2 treatment strategies for depressed inpatients: imipramine and lithium addition or mirtazapine and lithium addition. Bruijn, Dec 657–663
Introduction. Lithium in the treatment of manic-depressive illness: an update. Nemeroff, Suppl 6, 3–4
Key treatment studies of lithium in manic-depressive illness: efficacy and side effects. Bowden, Suppl 6, 13–19
Lithium augmentation of antidepressants in treatment-refractory depression. Heit, Suppl 6, 28–33
Lithium carbonate: maintenance studies and consequences of withdrawal. Dunner, Suppl 6, 48–55
Lithium treatment and risk of suicidal behavior in bipolar disorder patients. Tondo, Aug 405–414
Neurobiology of lithium: an update. Lenox, Suppl 6, 37–47
Special considerations: use of lithium in children, adolescents, and elderly populations. Tueth, Suppl 6, 66–73
Ups and downs of oral lithium dosing. Kilts, Suppl 6, 21–26
Use of lithium and management of women with bipolar disorder during pregnancy and lactation. Llewellyn, Suppl 6, 57–64
Use of lithium to augment antidepressant medication. Rouillon, Suppl 5, 32–39
Liver Function
Disulfiram use in patients with abnormal liver function test results. Saxon, June 313–316
Maintenance Treatment
Lithium carbonate: maintenance studies and consequences of withdrawal. Dunner, Suppl 6, 48–55
Loss of antidepressant efficacy during maintenance therapy: possible mechanisms and treatments. Byrne, June 279–288
Managed Care
Managed care versus managed money. Glazer, Suppl 2, 62–66
Managing behavioral health care: an employer's perspective. Davidson BN, Suppl 2, 9–12
Role of medication in managed care for depression. Glazer, Suppl 2, 67
Role of psychiatrists in managed care systems. Glazer, Suppl 2, 68
Mania
Bipolar depression and antidepressant-induced mania: a naturalistic study. Boerlin, July 374–379
Delirium with manic symptoms induced by diet pills [letter]. Bagri, Feb 83
Mania induced by risperidone: dose related? [letter] Lane, Feb 85–86
Naturalistic course of pharmacologic treatment of children with manic like symptoms: a systematic chart review [CME Article]. Biederman, Nov 628–637
Olanzapine-induced manic-like syndrome [letter]. Lindenmayer, June 318–319
Possible risks associated with valproate treatment of AIDS-related mania [letter]. Jefferson, June 317
Rapid titration of mood stabilizers predicts remission from mixed or pure mania in bipolar patients. Goldberg, Apr 151–158; Correction, June 320
Treatment algorithm use to optimize management of symptomatic patients with a history of mania [CME Article]. Suppes, Feb 89–96
Marijuana
Family history and early psychotogenic response to marijuana [letter]. Bowers, Apr 198–199
Mental Health Services, Delivery and Utilization of
American health care systems and depression: the past, present, and the future. Hirschfeld, Suppl 20, 5–10
Borderline personality symptomatology, experience of multiple types of trauma, and health care utilization among women in a primary care setting. Sansone, Mar 108–111
Psychiatric hospital utilization in patients treated with clozapine for up to 4.5 years in a state mental health care system. Reid, Apr 189–194

Methylphenidate
Methylphenidate treatment for cocaine abusers with adult attention-deficit/hyperactivity disorder: a pilot study. Levin, June 300–305
Metrifonate
Evaluating response to metrifonate. Tariot, Suppl 9, 33–37
M.I.N.I.-International Neuropsychiatric Interview
Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. Sheehan, Suppl 20, 22–33
M.I.N.I.: Mini-International Neuropsychiatric Interview, 5.0.0. Suppl 20, 34–57
Mirtazapine
Comparison of 2 treatment strategies for depressed inpatients: imipramine and lithium addition or mirtazapine and lithium addition. Bruijn, Dec 657–663
Hypomania associated with mirtazapine augmentation of sertraline [letter]. Soutullo, June 320
Meta-analysis of eight randomized, double-blind, controlled clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety. Fawcett, Mar 123–127
Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Wheatley, June 306–312
Safety of mirtazapine in overdose. Bremner, May 233–235
Sexual dysfunction associated with mirtazapine: a case report [letter]. Berigan, June 319–320
Moclobemide
Serotonin syndrome caused by a clomipramine-moclobemide interaction [letter]. Dardennes, July 382–383
Monoamine Oxidase Inhibitors
Problems with switching rapidly from one MAOI to another [letter]. Jefferson, Feb 87
Mood
Atypical antipsychotics for treatment of depression in schizophrenia and affective disorders. Collaborative Working Group, Suppl 12, 41–45
Clinical predictors of acute response with olanzapine in psychotic mood disorders. Zarate, Jan 24–28
Course of mood and anxiety disorders during pregnancy and the postpartum period. Altshuler, Suppl 2, 29–33
Gabapentin treatment of mood disorders: a preliminary study. Ghaemi, Aug 426–429
Nefazodone for mood disorder associated with epilepsy [letter]. Balon, Dec 690
Postpartum mood disorders: diagnosis and treatment guidelines. Nonacs, Suppl 2, 34–40
Recurrent mood shifts of premenstrual dysphoric disorder can be mistaken for rapid-cycling bipolar II disorder [letter]. Hendrick, Sept 479–480
Mood Stabilizers
Naturalistic course of pharmacologic treatment of children with maniclike symptoms: a systematic chart review [CME Article]. Biederman, Nov 628–637
Rapid titration of mood stabilizers predicts remission from mixed or pure mania in bipolar patients. Goldberg, Apr 151–158; Correction, June 320
Mortality
Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. Honigfeld, Suppl 3, 3–7
Mothers
Impact of maternal psychiatric illness on infant development. Weinberg, Suppl 2, 53–61
Movement Disorders
Movement disorders and psychotic symptoms treated with pyridoxine: a case report [letter]. Lerner V, Nov 623–624
Progression of abnormal involuntary movements during risperidone treatment [letter]. Sherr, Sept 478–479
Naltrexone
Naltrexone-induced reduction of tobacco intake [letter]. Lerner AG, Jan 30–31
Nefazodone
Double-blind, placebo-controlled trial of nefazodone in the treatment of patients hospitalized for major depression. Feighner, May 246–253
Nefazodone and the treatment of panic [letter]. Berigan, May 256–257
Nefazodone for mood disorder associated with epilepsy [letter]. Balon, Dec 690
Open trial of nefazodone for combat-related posttraumatic stress disorder. Hertzberg, Sept 460–464
Negative Symptoms
Assessing the effects of atypical antipsychotics on negative symptoms. Collaborative Working Group, Suppl 12, 28–34
Olanzapine and negative symptoms [letter]. Rosen; Ketter reply, Oct 537–538
Neuroimaging see Brain Imaging
Neuroleptic Malignant Syndrome
Is risk of neuroleptic malignant syndrome increased in the postpartum period? [letter] Alexander, May 254–255
Neuroleptics see Antipsychotics
Neurotrophic Growth Factors
Brain tonics for brain sprouts: how neurotrophic factors fertilize neurons [Brainstorms]. Stahl, Apr 149–150
When neurotrophic factors get on your nerves: therapy for neurodegenerative disorders [Brainstorms]. Stahl, June 277–278
Nicotine see Smoking
Nitric Oxide
Brain fumes: yes, we have NO brain gas [Brainstorms]. Stahl, Jan 6–7
Nitric oxide physiology and pharmacology [Brainstorms]. Stahl, Mar 101–102
Nortriptyline
Post hoc comparison of paroxetine and nortriptyline for symptoms of traumatic grief. Zygmont, May 241–245
Obesity
Neuropharmacology of obesity: my receptors made me eat it [Brainstorms]. Stahl, Sept 447–448
Obsessive-Compulsive Disorder
Clinical features distinguishing patients with Tourette's syndrome and obsessive-compulsive disorder from patients with obsessive-compulsive disorder without tics. Petter, Sept 456–459
Comparison study of body dysmorphic disorder and obsessive-compulsive disorder. Phillips, Nov 568–575
Gabapentin augmentation for fluoxetine-treated patients with obsessive-compulsive disorder [letter]. Corá-Locatelli, Sept 480–481
Hoarding and treatment response in 38 nondepressed subjects with obsessive-compulsive disorder. Black, Aug 420–425
Possible dose-response relationship for risperidone in obsessive-compulsive disorder [letter]. Baker; Stein reply, Mar 134
Risperidone may worsen fluoxetine-treated OCD [letter]. Andrade; Saxena reply, May 255–256
Valproate monotherapy in an SRI-intolerant OCD patient [letter]. Corá-Locatelli, Feb 82
Olanzapine
Acute dystonia with olanzapine [letter]. Landry, July 384
Clinical predictors of acute response with olanzapine in psychotic mood disorders. Zarate, Jan 24–28
Emergence of koro after abrupt cessation of olanzapine [letter]. Ramos, Feb 86–87
Hyperglycemia associated with olanzapine [letter]. Fertig, Dec 687–689
Olanzapine and negative symptoms [letter]. Rosen; Ketter reply, Oct 537–538
Olanzapine for the treatment of tardive dyskinesia [letter]. Almeida, July 380–381
Olanzapine-induced manic-like syndrome [letter]. Lindenmayer, June 318–319
Rapid efficacy of olanzapine augmentation in nonpsychotic bipolar mixed states [letter]. Ketter, Feb 83–85
Switching from clozapine to olanzapine in treatment-refractory schizophrenia: safety, clinical efficacy, and predictors of response. Henderson, Nov 585–588
Ondansetron
Treatment of venlafaxine discontinuation symptoms with ondansetron [letter]. Raby, Nov 621–622
Opioid Antagonists
Opioid antagonists in the treatment of impulse-control disorders. Kim, Apr 159–164
Outpatients
Individualized treatment for outpatients withdrawing from alcohol. Wiseman, June 289–293
Management of chronic psychotic ambulatory outpatients. Petty, Suppl 19, 30–35
Overdose
Safety in overdose of quetiapine: a case report [letter]. Nudelman, Aug 433
SSRI safety in overdose. Barbey, Suppl 15, 42–48
Panic
Antidepressants in panic disorder: clinical and preclinical mechanisms. Nutt, Suppl 8, 24–28
Cognitive-behavioral group therapy for panic disorder in the general clinical setting: a naturalistic study with 1-year follow-up [CME Article]. Martinsen, Aug 437–442
Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety. Ballenger, Suppl 8, 47–54
Controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder. Lepola, Oct 528–534
Impact of comorbidity on the treatment of panic disorder. Lecrubier, Suppl 8, 11–14
Introduction. Focus on panic disorder: antidepressants in practice. Ballenger, Suppl 8, 3
Long-term treatment of panic disorder. Davidson JRT, Suppl 8, 17–21
Medically unexplained symptoms in primary care. Katon, Suppl 20, 15–21

Nefazodone and the treatment of panic [letter]. Berigan, May 256–257
Pharmacotherapy of panic disorder: differential efficacy from a clinical viewpoint. den Boer, Suppl 8, 30–36
Road to recovery in panic disorder: response, remission, and relapse. Shear, Suppl 8, 4–8
Side effect burden associated with drug treatment of panic disorder. Baldwin, Suppl 8, 39–44
Paraphilias
Attention-deficit/hyperactivity disorder in males with paraphilias and paraphilia-related disorders: a comorbidity study [CME ARTICLE]. Kafka, July 388–396
Paroxetine
Dose-response efficacy of paroxetine in preventing depressive recurrences: a randomized, double-blind study. Franchini, May 229–232
Leukopenia associated with addition of paroxetine to clozapine [letter]. George, Jan 31
Paroxetine treatment of episodic rages associated with Tourette's disorder. Bruun, Nov 581–584
Post hoc comparison of paroxetine and nortriptyline for symptoms of traumatic grief. Zygmont, May 241–245
Patient Care
How do clinicians respond to patients who miss appointments? [CME ARTICLE] Smoller, June 330–338
Personality Disorder
Divalproex sodium for impulsive aggressive behavior in patients with personality disorder. Kavoussi, Dec 676–680
Pharmacokinetics
Pharmacokinetic interactions of antidepressants. Richelson, Suppl 10, 22–26
Pharmacotherapy
Pharmacotherapy of social anxiety disorder. Davidson JRT, Suppl 17, 47–51
Phenelzine
Stroke resulting from a rapid switch from phenelzine to tranylcypromine [letter]. Mattes, July 382
Phenobarbital
Elevated plasma clozapine concentrations after phenobarbital discontinuation [letter]. Lane, Mar 131–133
Phentermine
Bipolar depression associated with fenfluramine and phentermine [letter]. Zimmer, July 383–384
Phototherapy
Dawn simulation treatment of abstinent alcoholics with winter depression [CME ARTICLE]. Avery, Jan 36–42
Suicide after bright light treatment in seasonal affective disorder: a case report [letter]. Haffmans, Sept 478
Physical Appearance
Schizophrenia and changes in physical appearance. à Campo, Apr 197
Pindolol
Use of pindolol to potentiate antidepressant medication. Blier, Suppl 5, 16–23
Polydipsia
Absence of changes in antidiuretic hormone, angiotensin II, and atrial natriuretic peptide with clozapine treatment of polydipsia-hyponatremia: 2 case reports. Verghese, Aug 415–419
Postpartum Period
Course of mood and anxiety disorders during pregnancy and the postpartum period. Altshuler, Suppl 2, 29–33
Is risk of neuroleptic malignant syndrome increased in the postpartum period? [letter] Alexander, May 254–255
Postpartum mood disorders: diagnosis and treatment guidelines. Nonacs, Suppl 2, 34–40
Posttraumatic Stress Disorder
Open trial of nefazodone for combat-related posttraumatic stress disorder. Hertzberg, Sept 460–464
Prediction
Predictors of response to acute treatment of chronic and double depression with sertraline or imipramine. Hirschfeld, Dec 669–675
Pregnancy
Course of mood and anxiety disorders during pregnancy and the postpartum period. Altshuler, Suppl 2, 29–33
Psychotropic drug use during pregnancy: weighing the risks. Cohen, Suppl 2, 18–28
Use of lithium and management of women with bipolar disorder during pregnancy and lactation. Llewellyn, Suppl 6, 57–64
Premenstrual Disorders
Recurrent mood shifts of premenstrual dysphoric disorder can be mistaken for rapid-cycling bipolar II disorder [letter]. Hendrick, Sept 479–480
Treatment of premenstrual dysphoric disorder with sertraline during the luteal phase: a randomized, double-blind, placebo-controlled crossover trial. Young, Feb 76–80
Priapism
Priapism in a patient taking sertraline [letter]. Rand, Oct 538
Primary Care
Borderline personality symptomatology, experience of multiple types of trauma, and health care utilization among women in a primary care setting. Sansone, Mar 108–111
Can depression be managed appropriately in primary care? Simon, Suppl 2, 3–8
Depression in the family physician's office: what the psychiatrist needs to know: the Michigan Depression Project. Schwenk, Suppl 20, 94–100
Medically unexplained symptoms in primary care. Katon, Suppl 20, 15–21
Psychiatry
How do clinicians respond to patients who miss appointments? [CME ARTICLE] Smoller, June 330–338
Role of psychiatrists in managed care systems. Glazer, Suppl 2, 68
Psychomotor Retardation
Measurement of retardation in depression. Dantchev, Suppl 14, 19–25
Psychopharmacology
Basic psychopharmacology of antidepressants, part 1: antidepressants have seven distinct mechanisms of action. Stahl, Suppl 4, 5–14
Basic psychopharmacology of antidepressants, part 2: estrogen as an adjunct to antidepressant treatment. Stahl, Suppl 4, 15–24
Psychopharmacology of ADHD: children and adolescents. Findling, Suppl 7, 42–49
Psychopharmacology of noncognitive abnormal behaviors in Alzheimer's disease. Raskind, Suppl 9, 28–32
Psychosis
Emergency treatment of acute psychosis. Hillard, Suppl 1, 57–60
High association of anticardiolipin antibodies with psychosis. Schwartz, Jan 20–23
Movement disorders and psychotic symptoms treated with pyridoxine: a case report [letter]. Lerner V, Nov 623–624
Occurrence and clinical correlates of psychiatric comorbidity in patients with psychotic disorders. Cassano, Feb 60–68
Treatment of psychosis in late life. Zayas, Suppl 1, 5–10
Psychosocial Functioning
Treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine. Miller IW, Nov 608–619
Psychotherapy
Manual-based group psychotherapy for bipolar disorder: a feasibility study. Bauer, Sept 449–455
Self-administered psychotherapy for depression using a telephone-accessed computer system plus booklets: an open U.S.-U.K. study. Osgood-Hynes, July 358–365
Psychotropics
Psychotropic drug use during pregnancy: weighing the risks. Cohen, Suppl 2, 18–28
Psychotropic medications in lactation. Llewellyn, Suppl 2, 41–52
Pyridoxine
Movement disorders and psychotic symptoms treated with pyridoxine: a case report [letter]. Lerner V, Nov 623–624
Quetiapine
Inaccurate information on quetiapine [letter]. Goldstein; Masand reply, Dec 687
Safety in overdose of quetiapine: a case report [letter]. Nudelman, Aug 433
Reboxetine
Antidepressant efficacy and tolerability of the selective norepinephrine reuptake inhibitor reboxetine: a review. Burrows, Suppl 14, 4–7
Chairman's overview: the place of reboxetine in antidepressant therapy. Montgomery, Suppl 14, 26–29
Introduction. Reboxetine: a new selective antidepressant for the treatment of depression. Montgomery, Suppl 14, 3
Reboxetine versus fluoxetine: an overview of efficacy and tolerability. Massana, Suppl 14, 8–10
Recognition Molecules
Recognition molecules are trailblazers for axon pathways [BRAINSTORMS]. Stahl, May 215–216
Replantation
Upper-extremity self-amputation and replantation: 2 case reports and a review of the literature. Schlozman, Dec 681–686
Risperidone
Augmentation of risperidone with valproic acid [letter]. Chong, Aug 430
Clinical and neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenic patients: a prospective study. Lindenmayer, Oct 521–527
Edema associated with addition of risperidone to valproate treatment [letter]. Sanders, Dec 689–690
Mania induced by risperidone: dose related? [letter] Lane, Feb 85–86
Manic and psychotic symptoms following risperidone withdrawal in a schizophrenic patient [letter]. Lane, Nov 620–621
Possible dose-response relationship for risperidone in obsessive-compulsive disorder [letter]. Baker; Stein reply, Mar 134

Prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics. Miller CH, Feb 69–75
Progression of abnormal involuntary movements during risperidone treatment [letter]. Sherr, Sept 478–479
Relation of serum anticholinergicity to cognitive status in schizophrenia patients taking clozapine or risperidone. Tracy, Apr 184–188
Risperidone and allergic reactions [letter]. Terao, Feb 82–83
Risperidone-carbamazepine interactions: is cytochrome P450 3A involved? [letter] Lane; de Leon reply, Aug 430–431
Risperidone-induced tardive dyskinesia [letter]. Saran, Jan 29–30
Risperidone may worsen fluoxetine-treated OCD [letter]. Andrade; Saxena reply, May 255–256
Risperidone monotherapy for psychotic depression unresponsive to other treatments [letter]. Chang, Nov 624
Seizure during risperidone treatment in an elderly woman treated with concomitant medications [letter]. Lane, Feb 81–82
Schizophrenia
Assessing the effects of atypical antipsychotics on negative symptoms. Collaborative Working Group, Suppl 12, 28–34
Atypical antipsychotic agents in the treatment of schizophrenia and other psychiatric disorders, part I: unique patient populations [ACADEMIC HIGHLIGHTS]. May 259–265
Atypical antipsychotic agents in the treatment of schizophrenia and other psychiatric disorders, part II: special considerations [ACADEMIC HIGHLIGHTS]. June 322–328
Atypical antipsychotics for treatment of depression in schizophrenia and affective disorders. Collaborative Working Group, Suppl 12, 41–45
Clinical and neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenic patients: a prospective study. Lindenmayer, Oct 521–527
Clozapine reduces violence and persistent aggression in schizophrenia. Glazer, Suppl 3, 8–14
Effects of clozapine therapy in schizophrenic individuals at risk for tardive dyskinesia. Casey, Suppl 3, 31–37
Evaluating the effects of antipsychotics on cognition in schizophrenia. Collaborative Working Group, Suppl 12, 35–40
Introduction: new treatment options to improve clinical outcomes. McEvoy, Suppl 1, 3–4
Manic and psychotic symptoms following risperidone withdrawal in a schizophrenic patient [letter]. Lane, Nov 620–621
Measuring outcome in schizophrenia: differences among the atypical antipsychotics. Collaborative Working Group, Suppl 12, 3–9
Pharmacologic treatment of first-episode schizophrenia: early intervention is key to outcome. DeQuardo, Suppl 19, 9–17
Relation of serum anticholinergicity to cognitive status in schizophrenia patients taking clozapine or risperidone. Tracy, Apr 184–188
Schizophrenia and changes in physical appearance. à Campo, Apr 197
Substance abuse in schizophrenia: a review. Buckley, Suppl 3, 26–30
Suicide in schizophrenia: risk factors and clozapine treatment. Meltzer, Suppl 3, 15–20
Switching from clozapine to olanzapine in treatment-refractory schizophrenia: safety, clinical efficacy, and predictors of response. Henderson, Nov 585–588
Treatment and outcomes in adolescents with schizophrenia. Schulz, Suppl 1, 50–54
Treatment of special populations with the atypical antipsychotics. Collaborative Working Group, Suppl 12, 46–52
Treatment of the refractory schizophrenic patient. Daniel, Suppl 1, 13–19
Schizotypal Personality Disorder
Clinical outcome of psychopharmacologic treatment of borderline and schizotypal personality disordered subjects. Coccaro, Suppl 1, 30–35
Seasonal Affective Disorder
Dawn simulation treatment of abstinent alcoholics with winter depression [CME ARTICLE]. Avery, Jan 36–42
Suicide after bright light treatment in seasonal affective disorder: a case report [letter]. Haffmans, Sept 478
Selective Serotonin Reuptake Inhibitors see also specific drugs
Can bruxism respond to serotonin reuptake inhibitors? [letter] Stein, Mar 133
Discontinuation symptoms and SSRIs [letter]. Pollack; Schatzberg reply, Oct 535–537
Introduction: beyond SSRIs. Rush, Suppl 4, 3–4
Introduction. Optimizing clinical use of SSRIs: theory and practice. Glassman, Suppl 15, 3
Not so selective serotonin reuptake inhibitors [BRAINSTORMS]. Stahl, July 343–344
Randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression. Landén, Dec 664–668
SSRI safety in overdose. Barbey, Suppl 15, 42–48
Treatment of disequilibrium and nausea in the SRI discontinuation syndrome [letter]. Schechter, Aug 431–432
Use of selective serotonin reuptake inhibitors in eating disorders. Mayer, Suppl 15, 28–34
Self-Injurious Behavior
Upper-extremity self-amputation and replantation: 2 case reports and a review of the literature. Schlozman, Dec 681–686
Serotonin
Brain serotonin neurotransmission: an overview and update with an emphasis on serotonin subsystem heterogeneity, multiple receptors, interactions with other neurotransmitter systems, and consequent implications for understanding the actions of serotonergic drugs. Murphy, Suppl 15, 4–12
Using secondary binding properties to select a not so selective serotonin reuptake inhibitor [BRAINSTORMS]. Stahl, Dec 642–643
Serotonin Syndrome
Serotonin syndrome caused by a clomipramine-moclobemide interaction [letter]. Dardennes, July 382–383
Sertraline
Hypomania associated with mirtazapine augmentation of sertraline [letter]. Soutullo, June 320
Predictors of response to acute treatment of chronic and double depression with sertraline or imipramine. Hirschfeld, Dec 669–675
Priapism in a patient taking sertraline [letter]. Rand, Oct 538
Treatment of chronic depression, part 1: study design and rationale for evaluating the comparative efficacy of sertraline and imipramine as acute, crossover, continuation, and maintenance phase therapies. Rush, Nov 589–597
Treatment of chronic depression, part 2: a double-blind, randomized trial of sertraline and imipramine. Keller, Nov 598–607
Treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine. Miller IW, Nov 608–619
Treatment of premenstrual dysphoric disorder with sertraline during the luteal phase: a randomized, double-blind, placebo-controlled crossover trial. Young, Feb 76–80
Sex Offenders
Irradiation therapy prevents gynecomastia in sex offenders treated with antiandrogens [letter]. Eriksson, Aug 432–433
Sexual Function
Antidepressant-induced sexual dysfunction. Segraves, Suppl 4, 48–54
Bupropion as an antidote for serotonin reuptake inhibitor–induced sexual dysfunction. Ashton, Mar 112–115
How psychiatrists can build new therapies for impotence [BRAINSTORMS]. Stahl, 47–48
Sexual dysfunction associated with mirtazapine: a case report [letter]. Berigan, June 319–320
Side Effects see also specific side effects
Adverse effects of the atypical antipsychotics. Collaborative Working Group, Suppl 12, 17–22
Antidepressant drugs: disturbing and potentially dangerous adverse effects. Settle, Suppl 16, 25–30
Bupropion sustained release: side effect profile. Settle, Suppl 4, 32–36
Maximizing clozapine therapy: managing side effects. Lieberman, Suppl 3, 38–43
Selecting an antidepressant by using mechanism of action to enhance efficacy and avoid side effects. Stahl, Suppl 18, 23–29
Side effect burden associated with drug treatment of panic disorder. Baldwin, Suppl 8, 39–44
Sleep
Clinical and polysomnographic features of sleep-related eating disorder. Winkelman, Jan 14–19
Depression, sleep, and antidepressants. Thase, Suppl 4, 55–65
Differences in self-reported sleep complaints in elderly persons living in the community who do or do not take sleep medication [CME ARTICLE]. Englert, Mar 137–144
Smoking
Bupropion sustained release and smoking cessation. Goldstein, Suppl 4, 66–72
Naltrexone-induced reduction of tobacco intake [letter]. Lerner AG, Jan 30–31
Tobacco smoking and bipolar disorder. Gonzalez-Pinto, May 225–228
Social Anxiety Disorder
Brain mechanisms of social anxiety disorder. Nutt, Suppl 17, 4–9
Comorbidity in social anxiety disorder: impact on disease burden and management. Lecrubier, Suppl 17, 33–37
Consensus statement on social anxiety disorder from the International Consensus Group on Depression and Anxiety. Ballenger, Suppl 17, 54–60
How is recovery from social anxiety disorder defined? Bobes, Suppl 17, 12–16

Introduction: focus on social anxiety disorder. Ballenger, Suppl 17, 3
Nature of social anxiety disorder. Westenberg, Suppl 17, 20–24
Pharmacotherapy of social anxiety disorder. Davidson JRT, Suppl 17, 47–51
Psychotherapy in the overall management strategy for social anxiety disorder. Shear, Suppl 17, 39–44
Social anxiety disorder: etiology and early clinical presentation. Beidel, Suppl 17, 27–31
Somatization
Medically unexplained symptoms in primary care. Katon, Suppl 20, 15–21
St. John's Wort
St. John's wort and hypomania [letter]. Schneck, Dec 689
Stroke
Stroke resulting from a rapid switch from phenelzine to tranylcypromine [letter]. Mattes, July 382
Substance Abuse
Course of psychiatric and substance abuse syndromes co-occurring with bipolar disorder after a first psychiatric hospitalization. Strakowski, Sept 465–471
Substance abuse in schizophrenia: a review. Buckley, Suppl 3, 26–30
Substance Use Disorder
Medication compliance among patients with bipolar disorder and substance use disorder. Weiss, Apr 172–174
Suicide
Chronological assessment of suicide events: a practical interviewing strategy for the elicitation of suicidal ideation. Shea, Suppl 20, 58–72
Lithium treatment and risk of suicidal behavior in bipolar disorder patients. Tondo, Aug 405–414
Suicide after bright light treatment in seasonal affective disorder: a case report [letter]. Haffmans, Sept 478
Suicide in schizophrenia: risk factors and clozapine treatment. Meltzer, Suppl 3, 15–20
Tardive Dyskinesia
Assessment of EPS and tardive dyskinesia in clinical trials. Collaborative Working Group, Suppl 12, 23–27
Clozapine withdrawal–emergent dystonias and dyskinesias: a case series. Ahmed, Sept 472–477
Effects of clozapine therapy in schizophrenic individuals at risk for tardive dyskinesia. Casey, Suppl 3, 31–37
Olanzapine for the treatment of tardive dyskinesia [letter]. Almeida, July 380–381
Risperidone-induced tardive dyskinesia [letter]. Saran, Jan 29–30
Tests, Diagnostic
Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. Sheehan, Suppl 20, 22–33
M.I.N.I.: Mini-International Neuropsychiatric Interview, 5.0.0. Suppl 20, 34–57
Texas
ECT in Texas: 19 months of mandatory reporting. Reid, Jan 8–13
Texas Medication Algorithm Project: definitions, rationale, and methods to develop medication algorithms. Gilbert, July 345–351
Thyroid
Use of thyroid supplements to augment antidepressant medication. Joffe, Suppl 5, 26–39
Tobacco see Smoking
Tourette's Syndrome
Clinical features distinguishing patients with Tourette's syndrome and obsessive-compulsive disorder from patients with obsessive-compulsive disorder without tics. Petter, Sept 456–459
Paroxetine treatment of episodic rages associated with Tourette's disorder. Bruun, Nov 581–584
Rage attacks in children and adolescents with Tourette's disorder: a pilot study. Budman, Nov 576–580
Treatment of Tourette's syndrome: multimodal, developmental intervention. Peterson, Suppl 1, 62–72
Tranylcypromine
Stroke resulting from a rapid switch from phenelzine to tranylcypromine [letter]. Mattes, July 382
Trauma see also Posttraumatic Stress Disorder
Borderline personality symptomatology, experience of multiple types of trauma, and health care utilization among women in a primary care setting. Sansone, Mar 108–111
Treatment Algorithm
Texas Medication Algorithm Project: definitions, rationale, and methods to develop medication algorithms. Gilbert, July 345–351
Treatment algorithm use to optimize management of symptomatic patients with a history of mania [CME ARTICLE]. Suppes, Feb 89–96
Utilization see Mental Health Services
Valproate
Augmentation of risperidone with valproic acid [letter]. Chong, Aug 430
Edema associated with addition of risperidone to valproate treatment [letter]. Sanders, Dec 689–690
Possible risks associated with valproate treatment of AIDS-related mania [letter]. Jefferson, June 317
Valproate monotherapy in an SRI-intolerant OCD patient [letter]. Corá-Locatelli, Feb 82
Venlafaxine
Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. Thase, Oct 502–508
Large open-label study of venlafaxine in depressed outpatients by community-based physicians. Joffe, Oct 515–520
Once- versus twice-daily venlafaxine therapy in major depression: a randomized, double-blind study. Amsterdam, May 236–240
Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression. Costa e Silva, July 352–357
Randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. Rudolph, Mar 116–122
Treatment of venlafaxine discontinuation symptoms with ondansetron [letter]. Raby, Nov 621–622
Venlafaxine: loss of antidepressant effect and its management [letter]. Sharma, July 381–382
Violence
Clozapine reduces violence and persistent aggression in schizophrenia. Glazer, Suppl 3, 8–14
Weight
How to appease the appetite of psychotropic drugs [BRAINSTORMS]. Stahl, Oct 500–501
Withdrawal see Drug Discontinuation
Women
Borderline personality/symptomatology, experience of multiple types of trauma, and health care utilization among women in a primary care setting. Sansone, Mar 108–111
Use of lithium and management of women with bipolar disorder during pregnancy and lactation. Llewellyn, Suppl 6, 57–64

Journal of Clinical Psychiatry

Author Index to Volume 59: January 1998 Through December 1998

Aarre TF see Martinsen EW

Abraham G see Tracy JI; Verghese C

à Campo J, Frederikx M, Nijman H, Merckelbach H. Schizophrenia and changes in physical appearance. Apr 197

Agren H see Landén M

Ahmed S, Chengappa KNR, Naidu VR, Baker RW, Parepally H, Schooler NR. Clozapine withdrawal–emergent dystonias and dyskinesias: a case series. Sept 472–477

Aizpuru F see Gonzalez-Pinto A

Alarcon RD. Review of Akiskal HS, Cassano GB (eds): *Dysthymia and the Spectrum of Chronic Depressions.* Oct 539–540

Alexander PJ, Thomas RM, Das A. Is risk of neuroleptic malignant syndrome increased in the postpartum period? [letter] May 254–255

Allen D see Lindenmayer J-P

Almeida OP. Olanzapine for the treatment of tardive dyskinesia [letter]. July 380–381

Alpert JE see Nierenberg AA

Altshuler KZ see Gilbert DA; Rush AJ

Altshuler LL, Hendrick V, Cohen LS. Course of mood and anxiety disorders during pregnancy and the postpartum period. Suppl 2, 29–33

Altshuler LL see Hendrick V

Amchin J see Amsterdam JD

Amorim P see Sheehan DV

Amsterdam JD, Hooper MB, Amchin J. Once- versus twice-daily venlafaxine therapy in major depression: a randomized, double-blind study. May 236–240

Andrade C. Risperidone may worsen fluoxetine-treated OCD [letter with reply]. May 255–256

Andrews AM see Murphy DL

Apergi F-S see Lindenmayer J-P

Aquila R see Weiden PJ

Arellano F see Honigfeld G

Arnold LM, McElroy SL, Mutasim DF, Dwight MM, Lamerson CL, Morris EM. Characteristics of 34 adults with psychogenic excoriation. Oct 509–514

Ascher JA see Dunner DL

Ashton AK, Rosen RC. Bupropion as an antidote for serotonin reuptake inhibitor–induced sexual dysfunction. Mar 112–115

Atkinson JH see Zisook S

Attias D see Schwartz M

Avery DH, Bolte MA, Ries R. Dawn simulation treatment of abstinent alcoholics with winter depression [CME Article]. Jan 36–42

Baer L see Osgood-Hynes DJ

Bagri S, Reddy G. Delirium with manic symptoms induced by diet pills [letter]. Feb 83

Baker P see Black DW

Baker R see Sheehan DV

Baker RW. Possible dose-response relationship for risperidone in obsessive-compulsive disorder [letter with reply]. Mar 134

Baker RW, Chengappa KNR. Gastroesophageal reflux as a possible result of clozapine treatment [letter]. May 257

Baker RW see Ahmed S

Baldessarini RJ see George TP; Shelton RC; Tondo L

Baldwin DS, Birtwistle J. Side effect burden associated with drug treatment of panic disorder. Suppl 8, 39–44

Baldwin DS see Ballenger JC

Ballenger JC. Introduction. Focus on panic disorder: antidepressants in practice. Suppl 8, 3

Ballenger JC. Introduction: focus on social anxiety disorder. Suppl 17, 3

Ballenger JC, Davidson JRT, Lecrubier Y, Nutt DJ, Baldwin DS, den Boer JA, Kasper S, Shear MK. Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety. Suppl 8, 47–54

Ballenger JC, Davidson JRT, Lecrubier Y, Nutt DJ, Bobes J, Beidel DC, Ono Y, Westenberg HGM. Consensus statement on social anxiety disorder from the International Consensus Group on Depression and Anxiety. Suppl 17, 54–60

Ballon N see Dardennes RM

Balon R. Nefazodone for mood disorder associated with epilepsy [letter]. Dec 690

Bange F see Dardennes RM

Barbey JT, Roose SP. SSRI safety in overdose. Suppl 15, 42–48

Barkin RL see Fawcett J

Batey SR see Dunner DL

Bauer MS, McBride L, Chase C, Sachs G, Shea N. Manual-based group psychotherapy for bipolar disorder: a feasibility study. Sept 449–455

Beckham JC see Hertzberg MA

Beckman DA see McElroy SL

Beidel DC. Social anxiety disorder: etiology and early clinical presentation. Suppl 17, 27–31

Beidel DC see Ballenger JC; Shear MK

Bell CJ see Nutt DJ

Benedek DM see Young SA

Benedetti F, Sforzini L, Colombo C, Maffei C, Smeraldi E. Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder. Mar 103–107

Bennett ME see Feighner J

Berber MJ. FINISH: remembering the discontinuation syndrome [letter]. May 255

Bergeron R see Blier P

Berigan TR, Casas A, Harazin J. Nefazodone and the treatment of panic [letter]. May 256–257

Berigan TR, Harazin JS. Sexual dysfunction associated with mirtazapine: a case report [letter]. June 319–320

Berman A see Zarate CA Jr

Bernet W. Review of Gutheil TG: *The Psychiatrist as Expert Witness.* Mar 135

Bernet W. Review of Gutheil TG: *The Psychiatrist in Court: A Survival Guide.* Mar 135

Bernet W. Review of Wettstein RM (ed): *Treatment of Offenders With Mental Disorders.* Nov 626

Best TS see Lanctôt KL

Bianchini A see Honigfeld G

Biederman J. Attention-deficit/hyperactivity disorder: a life-span perspective. Suppl 7, 4–16

Biederman J, Mick E, Bostic JQ, Prince J, Daly J, Wilens TE, Spencer T, Garcia-Jetton J, Russell R, Wozniak J, Faraone SV. Naturalistic course of pharmacologic treatment of children with manicklike symptoms: a systematic chart review [CME Article]. Nov 628–637

Biederman J see Spencer T

Billow AA see Dunner DL

Birtwistle J see Baldwin DS

Björling G see Landén M

Black DW, Monahan P, Gable J, Blum N, Clancy G, Baker P. Hoarding and treatment response in 38 nondepressed subjects with obsessive-compulsive disorder. Aug 420–425

Blier P, Bergeron R. Use of pindolol to potentiate antidepressant medication. Suppl 5, 16–23

Blum N see Black DW

Bobes J. How is recovery from social anxiety disorder defined? Suppl 17, 12–16

Bobes J see Ballenger JC

Boerlin HL, Gitlin MJ, Zoellner LA, Hammen CL. Bipolar depression and antidepressant-induced mania: a naturalistic study. July 374–379

Bolte MA see Avery DH

Bork J see de Leon J

Bostic JQ see Biederman J

Bouwer C see Stein DJ

Bowden CL. Key treatment studies of lithium in manic-depressive illness: efficacy and side effects. Suppl 6, 13–19

Bowers MB Jr. Family history and early psychotogenic response to marijuana [letter]. Apr 198–199

Brawman-Mintzer O see Lydiard RB

Bremner JD, Wingard P, Walshe TA. Safety of mirtazapine in overdose. May 233–235

Briggs MJ see Wiseman EJ

Brooks BA. Review of Steiner H (ed): *Treating Preschool Children.* Sept 482

Brooks BA. Review of Steiner H (ed): *Treating School-Age Children.* Sept 482

Brooks VG see Fertig MK

Bruijn JA, Moleman P, Mulder PGH, van den Broek WW. Comparison of 2 treatment strategies for depressed inpatients: imipramine and lithium addition or mirtazapine and lithium addition. Dec 657–663

Bruun RD, Budman CL. Paroxetine treatment of episodic rages associated with Tourette's disorder. Nov 581–584

Bruun RD see Budman CL

Buckley PF. Substance abuse in schizophrenia: a review. Suppl 3, 26–30
Budman CL, Bruun RD, Park KS, Olson ME. Rage attacks in children and adolescents with Tourette's disorder: a pilot study. Nov 576–580
Budman CL see Bruun RD; Ramos RH
Buitelaar JK, van der Gaag RJ, van der Hoeven J. Buspirone in the management of anxiety and irritability in children with pervasive developmental disorders: results of an open-label study. Feb 56–59
Burrows GD, Maguire KP, Norman TR. Antidepressant efficacy and tolerability of the selective norepinephrine reuptake inhibitor reboxetine: a review. Suppl 14, 4–7
Buzan RD, Dubovsky SL. Recurrence of lamotrigine-associated rash with rechallenge [letter]. Feb 87
Byrne SE, Rothschild AJ. Loss of antidepressant efficacy during maintenance therapy: possible mechanisms and treatments. June 279–288
Bystritsky A see Saxena S
Cantwell DP. ADHD through the life span: the role of bupropion in treatment. Suppl 4, 92–94
Carpenter D see Frances AJ
Carter W see Phillips KA
Casas A see Berigan TR
Casey DE. Effects of clozapine therapy in schizophrenic individuals at risk for tardive dyskinesia. Suppl 3, 31–37
Cassano GB, Pini S, Saettoni M, Rucci P, Dell'Osso L. Occurrence and clinical correlates of psychiatric comorbidity in patients with psychotic disorders. Feb 60–68
Centorrino F see George TP
Chang W-H, Lane H-Y. Manic and psychotic symptoms following risperidone withdrawal in a schizophrenic patient [letter]. Nov 620–621
Chang W-H, Lane H-Y. Risperidone monotherapy for psychotic depression unresponsive to other treatment [letter]. Nov 624
Chang W-H see Lane H-Y
Charney DS. Introduction: current issues in attention deficit disorder. Suppl 7, 3
Charney DS. Monoamine dysfunction and the pathophysiology and treatment of depression. Suppl 14, 11–14
Charron M see Damecour CL
Chase C see Bauer MS
Chengappa KNR see Ahmed S; Baker RW; Levine J
Chong S-A, Tan C-H, Lee E-L, Liow P-H. Augmentation of risperidone with valproic acid [letter]. Aug 430
Chou JC-Y see Lane H-Y
Clancy G see Black DW
Clark D see Shear MK
Clayton PJ. Depression subtyping: treatment implications. Suppl 16, 5–12
Coccaro EF. Clinical outcome of psychopharmacologic treatment of borderline and schizotypal personality disordered subjects. Suppl 1, 30–35
Coccaro EF see Kavoussi RJ
Cohen CI see Nudelman E
Cohen DJ see Peterson BS
Cohen LS, Rosenbaum JF. Psychotropic drug use during pregnancy: weighing the risks. Suppl 2, 18–28
Cohen LS see Altshuler LL; Nonacs R
Collaborative Working Group on Clinical Trial Evaluations. Adverse effects of the atypical antipsychotics. Suppl 12, 17–22
Collaborative Working Group on Clinical Trial Evaluations. Assessing the effects of atypical antipsychotics on negative symptoms. Suppl 12, 28–34
Collaborative Working Group on Clinical Trial Evaluations. Assessment of EPS and tardive dyskinesia in clinical trials. Suppl 12, 23–27
Collaborative Working Group on Clinical Trial Evaluations. Atypical antipsychotics for treatment of depression in schizophrenia and affective disorders. Suppl 12, 41–45
Collaborative Working Group on Clinical Trial Evaluations. Clinical development of atypical antipsychotics: research design and evaluation. Suppl 12, 10–16
Collaborative Working Group on Clinical Trial Evaluations. Evaluating the effects of antipsychotics on cognition in schizophrenia. Suppl 12, 35–40
Collaborative Working Group on Clinical Trial Evaluations. Measuring outcome in schizophrenia: differences among the atypical antipsychotics. Suppl 12, 3–9
Collaborative Working Group on Clinical Trial Evaluations. Treatment of special populations with the atypical antipsychotics. Suppl 12, 46–52
Colombo C see Benedetti F
Conley RR. Optimizing treatment with clozapine. Suppl 3, 44–48
Conners CK. Rating scales in attention-deficit/hyperactivity disorder: use in assessment and treatment monitoring. Suppl 7, 24–30
Connolly MA see Hirschfeld RMA
Connor KM see Davidson JRT
Corá-Locatelli G, Greenberg BD, Martin JD, Murphy DL. Gabapentin augmentation for fluoxetine-treated patients with obsessive-compulsive disorder [letter]. Sept 480–481
Corá-Locatelli G, Greenberg BD, Martin JD, Murphy DL. Rebound psychiatric and physical symptoms after gabapentin discontinuation [letter]. Mar 131
Corá-Locatelli G, Greenberg BD, Martin JD, Murphy DL. Valproate monotherapy in an SRI-intolerant OCD patient [letter]. Feb 82
Coryell W. Treatment of psychotic depression. Suppl 1, 22–27
Costa e Silva J. Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression. July 352–357
Cournoyer J see Landry P
Coyne JC see Schwenk TL
Crismon ML see Gilbert DA; Rush AJ
Cummings JL. Introduction: Alzheimer's disease management. Suppl 13, 4–5
Cummings JL, Masterman DL. Assessment of treatment-associated changes in behavior and cholinergic therapy of neuropsychiatric symptoms in Alzheimer's disease. Suppl 13, 23–30
Czobor P see Lindenmayer J-P
Dahlqvist R see Hägg S
Daly J see Biederman J
Damecour CL, Charron M. Hoarding: a symptom, not a syndrome [CME Article]. May 267–272
D'Amico MF see Feighner J
Daniel DG, Whitcomb SR. Treatment of the refractory schizophrenic patient. Suppl 1, 13–19
Dantchev N, Widlöcher DJ. Measurement of retardation in depression. Suppl 14, 19–25
Dardennes RM, Even C, Ballon N, Bange F. Serotonin syndrome caused by a clomipramine-moclobemide interaction [letter]. July 382–383
Das A see Alexander PJ
Dashevsky BA, Kramer M. Behavioral treatment of chronic insomnia in psychiatrically ill patients [CME Article]. Dec 693–699
Davidoff DA see Verma SD
Davidson BN. Managing behavioral health care: an employer's perspective. Suppl 2, 9–12
Davidson JRT. Long-term treatment of panic disorder. Suppl 8, 17–21
Davidson JRT. Pharmacotherapy of social anxiety disorder. Suppl 17, 47–51
Davidson JRT, Connor KM. Bupropion sustained release: a therapeutic overview. Suppl 4, 25–31
Davidson JRT see Ballenger JC; Hertzberg MA
Davis KL. Future therapeutic approaches to Alzheimer's disease. Suppl 11, 14–16
Davis KL see Schneider LS
Davis SM see Keller MB; Miller IW
DeGolia SG see Ketter TA
de Leon J. Reply to Lane H-Y: Risperidone-carbamazepine interactions: is cytochrome P450 3A involved? [letter] Aug 431
de Leon J see Gonzalez-Pinto A; Verghese C
Delgado PL see Hirschfeld RMA
Dell'Osso L see Cassano GB
DeLuca P see Ellison JM
den Boer JA. Pharmacotherapy of panic disorder: differential efficacy from a clinical viewpoint. Suppl 8, 30–36
den Boer JA see Ballenger JC
DeQuardo JR. Pharmacologic treatment of first-episode schizophrenia: early intervention is key to outcome. Suppl 19, 9–17
Derivan AT see Rudolph RL
Desai SP see Ghaemi SN
DeVane CL. Differential pharmacology of newer antidepressants. Suppl 20, 85–93
Dickson RA see Glazer WM
Dietrich DE, Emrich HM. Use of anticonvulsants to augment antidepressant medication. Suppl 5, 51–58
Docherty JP see Frances AJ
Dogin JW see Findling RL
Donovan SL see Frances AJ
Doraiswamy PM, Steffens DC, Pitchumoni S, Tabrizi S. Early recognition of Alzheimer's disease: what is consensual? what is controversial? what is practical? Suppl 13, 6–18
Dottl SL see Osgood-Hynes DJ
Dougherty D see Nierenberg AA
Downs NS see Zisook S
Dubovsky SL see Buzan RD
Dunai M see Ketter TA
Dunbar GC see Sheehan DV
Duncan BA, Siegal AP. Early diagnosis and management of Alzheimer's disease. Suppl 9, 15–21
Dunner DL. Lithium carbonate: maintenance studies and consequences of withdrawal. Suppl 6, 48–55
Dunner DL, Zisook S, Billow AA, Batey SR, Johnston JA, Ascher JA. Prospective safety surveillance study for bupropion sustained-release in the treatment of depression. July 366–373
Dwight MM see Arnold LM; Phillips KA
Ebert MH. Review of Ciraulo DA, Shader RI, Greenblatt DJ, Creelman W: *Drug Interactions in Psychiatry, 2nd ed.* Aug 434–435
Ebert MH. Review of Cooper JR, Bloom FE, Roth RH: *The Biochemical Basis of Neuropharmacology, 7th ed.* May 258
Ebert MH. Review of Stahl SM: *Essential Psychopharmacology: Neuroscientific Basis and Practical Applications.* May 258
Einarson TR see Lanctôt KL

Eldar I see Schwartz M
Ellison JM, DeLuca P. Fluoxetine-induced genital anesthesia relieved by *Ginkgo biloba* extract [letter]. Apr 199–200
Emanuel M see Weiden PJ
Emrich HM see Dietrich DE
Emsley RA see Stein DJ
Englert S, Linden M. Differences in self-reported sleep complaints in elderly persons living in the community who do or do not take sleep medication [CME ARTICLE]. Mar 137–144
English CW see Fertig MK
Entsuah R see Rudolph RL
Eriksson M see Eriksson T
Eriksson T, Eriksson M. Irradiation therapy prevents gynecomastia in sex offenders treated with antiandrogens [letter]. Aug 432–433
Eto A see Terao T
Evans DL see Tueth MJ
Evans SM see Levin FR
Even C see Dardennes RM
Ezcurra J see Gonzalez-Pinto A
Fabre LF see Rudolph RL
Fahlén T see Landén M
Faraone SV see Biederman J; Spencer T
Fava M. Depression with anger attacks. Suppl 18, 18–22
Fava M see Nierenberg AA
Fawcett J, Barkin RL. Meta-analysis of eight randomized, double-blind, controlled clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety. Mar 123–127
Fawcett J see Hirschfeld RMA
Fawcett JA see Keller MB; Rush AJ
Feighner J, Targum SD, Bennett ME, Roberts DL, Kensler TT, D'Amico MF, Hardy SA. Double-blind, placebo-controlled trial of nefazodone in the treatment of patients hospitalized for major depression. May 246–253
Feighner JP see Rudolph RL
Feldman ME see Hertzberg MA
Fertig MK, Brooks VG, Shelton PS, English CW. Hyperglycemia associated with olanzapine [letter]. Dec 687–689
Feske U see Shear MK
Findling RL, Dogin JW. Psychopharmacology of ADHD: children and adolescents. Suppl 7, 42–49
Findling RL see Schulz SC
Fleischhacker WW see Miller CH
Floris G see Tondo L
Frances AJ, Kahn DA, Carpenter D, Docherty JP, Donovan SL. Expert consensus guidelines for treating depression in bipolar disorder. Suppl 4, 73–79
Franchini L, Gasperini M, Perez J, Smeraldi E, Zanardi R. Dose-response efficacy of paroxetine in preventing depressive recurrences: a randomized, double-blind study. May 229–232
Frazer J see Lepola UM
Frederikx M see à Campo J
Friedman ES see Thase ME
Friedman L see Schulz SC
Friedman RA see Hirschfeld RMA
Gable J see Black DW
Galin RS see Sclar DA
Garcia-España F see Schweizer E
Garcia-Jetton J see Biederman J
Garno JL see Goldberg JF
Gasperini M see Franchini L
Gelenberg AJ. Apologies and thanks to reviewers [letter]. April 195
Gelenberg AJ see Keller MB; Rush AJ
George TP, Innamorato L, Sernyak MJ, Baldessarini RJ, Centorrino F. Leukopenia associated with addition of paroxetine to clozapine [letter]. Jan 31
Ghaemi SN, Katzow JJ, Desai SP, Goodwin FK. Gabapentin treatment of mood disorders: a preliminary study. Aug 426–429
Gilbert DA, Altshuler KZ, Rago WV, Shon SP, Crismon ML, Toprac MG, Rush AJ. Texas Medication Algorithm Project: definitions, rationale, and methods to develop medication algorithms. July 345–351
Gitlin MJ see Boerlin HL
Glassman AH. Cardiovascular effects of antidepressant drugs: updated. Suppl 15, 13–18
Glassman AH. Introduction. Optimizing clinical use of SSRIs: theory and practice. Suppl 15, 3
Glassman AH, Rodriguez AI, Shapiro PA. Use of antidepressant drugs in patients with heart disease. Suppl 10, 16–21
Glazer WM. Formulary decisions and health economics. Suppl 19, 23–29
Glazer WM, Dickson RA. Clozapine reduces violence and persistent aggression in schizophrenia. Suppl 3, 8–14
Glazer WM, Rosenbaum JF. Managed care versus managed money. Suppl 2, 62–66
Glazer WM, Rosenbaum JF. Role of medication in managed care for depression. Suppl 2, 67
Glazer WM, Rosenbaum JF. Role of psychiatrists in managed care systems. Suppl 2, 68
Goff DC see Henderson DC
Goggin KJ see Zisook S
Golan D see Schwartz M
Gold DD Jr. Review of Bellack AS, Mueser KT, Gingerich S, Agresta J: *Social Skills Training for Schizophrenia: A Step-by-Step Guide.* Aug 435
Gold DD Jr. Review of Tsuang MT, Faraone SV: *Schizophrenia: The Facts, Second Edition.* July 385–386
Goldberg JF, Garno JL, Leon AC, Kocsis JH, Portera L. Rapid titration of mood stabilizers predicts remission from mixed or pure mania in bipolar patients. Apr 151–158. Correction, June 320
Goldstein JM. Inaccurate information on quetiapine [letter with reply]. Dec 687
Goldstein MG. Bupropion sustained release and smoking cessation. Suppl 4, 66–72
Gonzalez-Pinto A, Gutierrez M, Ezcurra J, Aizpuru F, Mosquera F, Lopez P, de Leon J. Tobacco smoking and bipolar disorder. May 225–228
Goodwin FK see Ghaemi SN
Gorwood P see Rouillon F
Grant I see Zisook S
Greaney JJ see Zarate CA Jr
Greenberg BD see Corá-Locatelli G; Murphy DL
Greenblatt DJ, von Moltke LL, Harmatz JS, Shader RI. Drug interactions with newer antidepressants: role of human cytochromes P450. Suppl 15, 19–27
Greenfield SF see Weiss RD
Greenhill LL. Diagnosing attention-deficit/hyperactivity disorder in children. Suppl 7, 31–41
Gregory RJ see Zimmer JE
Greist JH. Computer interviews for depression management. Suppl 16, 20–24
Greist JH see Osgood-Hynes DJ
Griffin ML see Weiss RD
Grossberg GT, Lake JT. Role of the psychiatrist in Alzheimer's disease. Suppl 9, 3–6
Grossberg GT see Zayas EM
Grothaus L see Simon GE
Gunderson CG see Phillips KA
Gutierrez M see Gonzalez-Pinto A
Haffmans J, Lucius S, Ham N. Suicide after bright light treatment in seasonal affective disorder: a case report [letter]. Sept 478
Hägg S, Joelsson L, Mjörndal T, Spigset O, Oja G, Dahlqvist R. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. June 294–299
Ham N see Haffmans J
Hammen CL see Boerlin HL
Harazin JS see Berigan TR
Hardy SA see Feighner J
Harmatz JS see Greenblatt DJ
Harrison WM see Hirschfeld RMA; Keller MB; Miller IW; Rush AJ
Hassman H see Schweizer E
Haver VM see Saxon AJ
Hawkins JM see Strakowski SM
Hawkridge S see Stein DJ
Heiligenstein JH see Simon GE
Heit S, Nemeroff CB. Lithium augmentation of antidepressants in treatment-refractory depression. Suppl 6, 28–33
Henderson DC, Nasrallah RA, Goff DC. Switching from clozapine to olanzapine in treatment-refractory schizophrenia: safety, clinical efficacy, and predictors of response. Nov 585–588
Henderson KL see Wiseman EJ
Hendrick V, Altshuler LL. Recurrent mood shifts of premenstrual dysphoric disorder can be mistaken for rapid-cycling bipolar II disorder [letter]. Sept 479–480
Hendrick V see Altshuler LL
Heneman SW see Osgood-Hynes DJ
Hennen J see Tondo L
Hergueta T see Sheehan DV
Hertzberg MA, Feldman ME, Beckham JC, Moore SD, Davidson JRT. Open trial of nefazodone for combat-related posttraumatic stress disorder. Sept 460–464
Hillard JR. Emergency treatment of acute psychosis. Suppl 1, 57–60
Hirschfeld RMA. American health care systems and depression: the past, present, and the future. Suppl 20, 5–10
Hirschfeld RMA, Russell JM, Delgado PL, Fawcett J, Friedman RA, Harrison WM, Koran LM, Miller IW, Thase ME, Howland RH, Connolly MA, Miceli RJ. Predictors of response to acute treatment of chronic and double depression with sertraline or imipramine. Dec 669–675
Hirschfeld RMA see Keller MB; Rush AJ
HIV Neurobehavioral Research Center Group see Zisook S
Hoek HW see van Harten PN
Holmes S. Correction [letter with reply]. Nov 620
Honigfeld G, Arellano F, Sethi J, Bianchini A, Schein J. Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. Suppl 3, 3–7
Hooper MB see Amsterdam JD
Hornig M. Addressing comorbidity in adults with attention-deficit/hyperactivity disorder. Suppl 7, 69–75
Horwitz EH see van Harten PN
Houck PR see Zygmont M
Howard RS see Young SA
Howland RH see Hirschfeld RMA; Thase ME
Hubbard JR. Review of Kranzler HR, Rounsaville

BJ (eds): *Dual Diagnosis and Treatment: Substance Abuse and Comorbid Medical and Psychiatric Disorders.* Nov 625
Hurt PH see Young SA
Innamorato L see George TP
Iskander A see Lindenmayer J-P
Jacobs S see Zygmont M
Janavs J see Sheehan DV
Jann MW see Lane W-H
Jefferson JW. Drug and diet interactions: avoiding therapeutic paralysis. Suppl 16, 31–39
Jefferson JW. Drug interactions—friend or foe? Suppl 4, 37–47
Jefferson JW. Introduction. Depressive disorders: advances in clinical management. Suppl 16, 3–4
Jefferson JW. Possible risks associated with valproate treatment of AIDS-related mania [letter]. June 317
Jefferson JW. Problems with switching rapidly from one MAOI to another [letter]. Feb 87
Joelsson L see Hägg S
Joffe RT. Use of thyroid supplements to augment antidepressant medication. Suppl 5, 26–29
Joffe RT, Marshall AM, Lee DK. Large open-label study of venlafaxine in depressed outpatients by community-based physicians. Oct 515–520
Joffe RT see Sussman N
Johnston JA see Dunner DL
Josiassen RC see Tracy JI
Kafka MP, Prentky RA. Attention-deficit/hyperactivity disorder in males with paraphilias and paraphilia-related disorders: a comorbidity study [CME ARTICLE]. July 388–396
Kahn DA see Frances AJ
Kalin NH. Commentary: the contemporary use of lithium. Suppl 6, 35–36
Kambhampati KK see Verma SD
Kasper S see Ballenger JC
Katon WJ. Introduction. Depression and anxiety: new tools for diagnosis and treatment. Suppl 20, 3–4
Katon WJ, Walker EA. Medically unexplained symptoms in primary care. Suppl 20, 15–21
Katon WJ see Simon GE
Katz IR. Diagnosis and treatment of depression in patients with Alzheimer's disease and other dementias. Suppl 9, 38–44
Katzow JJ see Ghaemi SN
Kavoussi RJ, Coccaro EF. Divalproex sodium for impulsive aggressive behavior in patients with personality disorder. Dec 676–680
Keck PE Jr, McElroy SL, Strakowski SM. Anticonvulsants and antipsychotics in the treatment of bipolar disorder. Suppl 6, 74–81
Keck PE Jr see McElroy SL; Soutullo CA; Strakowski SM
Keitner GI see Miller IW
Keller MB, Gelenberg AJ, Hirschfeld RMA, Rush AJ, Thase ME, Kocsis JH, Markowitz JC, Fawcett JA, Koran LM, Klein DN, Russell JM, Kornstein SG, McCullough JP, Davis SM, Harrison WM. Treatment of chronic depression, part 2: a double-blind, randomized trial of sertraline and imipramine. Nov 598–607
Keller MB see Miller IW; Rush AJ
Keller S see Reid WH
Kenny JT see Schulz SC
Kensler TT see Feighner J
Ketter TA, Winsberg ME, DeGolia SG, Dunai M, Tate DL, Strong CM. Rapid efficacy of olanzapine augmentation in nonpsychotic bipolar mixed states [letter]. Feb 83–85
Ketter TA, Winsberg ME, DeGolia SG, Dunai M, Tate DL, Strong CM. Reply to Rosen EH: Olanzapine and negative symptoms [letter]. Oct 537–538
Kilts CD. Ups and downs of oral lithium dosing. Suppl 6, 21–26
Kim SW. Opioid antagonists in the treatment of impulse-control disorders. Apr 159–164
Kinon BJ. Routine use of atypical antipsychotic agents: maintenance treatment. Suppl 19, 18–22
Klebanov R see Lindenmayer J-P
Kleber HD see Levin FR
Klein DN see Keller MB; Miller IW; Rush AJ
Klinkman MS see Schwenk TL
Kocsis JH. Geriatric dysthymia. Suppl 10, 13–15
Kocsis JH see Goldberg JF; Keller MB; Rush AJ
Kojima H see Terao T
Koponen HJ see Lepola UM
Koran LM see Hirschfeld RMA; Keller MB; Rush AJ
Kornstein SG see Keller MB; Miller IW
Kowatch R see Shelton RC
Kraemer HC see Suppes T
Kramer M see Dashevsky BA
Kremer CM see Wheatley DP
Kwentus JA. Review of Nelson JC (ed): *Geriatric Psychopharmacology.* Nov 625–626
Lake JT see Grossberg GT
Lamerson CL see Arnold LM
Lanctôt KL, Best TS, Mittmann N, Liu BA, Oh PI, Einarson TR, Naranjo CA. Efficacy and safety of neuroleptics in behavioral disorders associated with dementia [CME ARTICLE]. Oct 550–561
Landén M, Björling G, Agren H, Fahlén T. Randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression. Dec 664–668
Landry P, Cournoyer J. Acute dystonia with olanzapine [letter]. July 384
Lane H-Y, Chang W-H. Manic and psychotic symptoms following risperidone withdrawal in a schizophrenic patient [letter]. Nov 620–621
Lane H-Y, Chang W-H. Risperidone-carbamazepine interactions: is cytochrome P450 3A involved? [letter with reply] Aug 430–431
Lane H-Y, Chang W-H. Risperidone monotherapy for psychotic depression unresponsive to other treatments [letter]. Nov 624
Lane H-Y, Chang W-H, Chou JC-Y. Seizure during risperidone treatment in an elderly woman treated with concomitant medications [letter]. Feb 81–82
Lane H-Y, Lin Y-C, Chang W-H. Mania induced by risperidone: dose related? [letter] Feb 85–86
Lane H-Y, Su K-P, Chang W-H, Jann MW. Elevated plasma clozapine concentrations after phenobarbital discontinuation [letter]. Mar 131–133
Lane H-Y see Chang W-H
Laor N see Toren P
Lauterbach EC, Meyer JM, Simpson GM. Article commended [letter]. Mar 133
Lawrie SM. Attacks of jealousy that responded to clomipramine [letter]. June 317–318
Leatherman M see Reid WH
Lecrubier Y. Comorbidity in social anxiety disorder: impact on disease burden and management. Suppl 17, 33–37
Lecrubier Y. Impact of comorbidity on the treatment of panic disorder. Suppl 8, 11–14
Lecrubier Y see Ballenger JC; Sheehan DV
Lee DK see Joffe RT
Lee E-L see Chong S-A
Legg RF see Sclar DA
Lehrer DS see Sanders RD
Lehto HJ see Lepola UM
Leinonen EV see Lepola UM
Leiter F see Small GW
Lenox RH, McNamara RK, Papke RL, Manji HK. Neurobiology of lithium: an update. Suppl 6, 37–47
Leon AC see Goldberg JF
Lepola UM, Wade AG, Leinonen EV, Koponen HJ, Frazer J, Sjödin I, Penttinen JT, Pedersen T, Lehto HJ. Controlled prospective, 1-year trial of citalopram in the treatment of panic disorder. Oct 528–534
Lerner AG, Oyffe I, Sigal M. Naltrexone-induced reduction of tobacco intake [letter]. Jan 30–31
Lerner V, Liberman M. Movement disorders and psychotic symptoms treated with pyridoxine: a case report [letter]. Nov 623–624
Levin FR, Evans SM, McDowell DM, Kleber HD. Methylphenidate treatment for cocaine abusers with adult attention-deficit/hyperactivity disorder: a pilot study. June 300–305
Levine J, Chengappa KNR. Second thoughts about clozapine as a treatment for neuroleptic-induced akathisia [letter]. Apr 195
Li Q see Murphy DL
Liberman M see Lerner V
Lieberman JA. Maximizing clozapine therapy: managing side effects. Suppl 3, 38–43
Lieberman JA see Miller CH
Lin Y-C see Lane H-Y
Linden M see Englert S
Lindenmayer J-P, Iskander A, Park M, Apergi F-S, Czobor P, Smith R, Allen D. Clinical and neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenic patients: a prospective study. Oct 521–527
Lindenmayer J-P, Klebanov R. Olanzapine-induced manic-like syndrome [letter]. June 318–319
Liotta W see Zametkin AJ
Liow P-H see Chong S-A
Liu BA see Lanctôt KL
Llewellyn A, Stowe ZN. Psychotropic medications in lactation. Suppl 2, 41–52
Llewellyn A, Stowe ZN, Strader JR Jr. Use of lithium and management of women with bipolar disorder during pregnancy and lactation. Suppl 6, 57–64
Lopez P see Gonzalez-Pinto A
Lucht MJ, Rietschel M. Clozapine-induced eosinophilia: subsequent neutropenia and corresponding allergic mechanisms [letter]. Apr 195–197
Lucius S see Haffmans P
Lydiard RB, Brawman-Mintzer O. Anxious depression. Suppl 18, 10–17
Madrid A see Zarate CA Jr
Maffei C see Benedetti F
Maguire KP see Burrows GD
Malizia AL see Nutt DJ
Mallya G see Phillips KA
Manji HK see Lenox RH
Manzo PA see Osgood-Hynes DJ
Maragakis BP see Bremner JD
Marder SR. Facilitating compliance with antipsychotic medication. Suppl 3, 21–25
Markowitz JC see Keller MB; Miller IW; Rush AJ
Marks IM see Osgood-Hynes DJ
Marshall AM see Joffe RT
Martin JD see Corá-Locatelli G
Martinsen EW, Olsen T, Tonset E, Nyland KE, Aarre TF. Cognitive-behavioral group therapy for panic disorder in the general clinical setting:

a naturalistic study with 1-year follow-up [CME ARTICLE]. Aug 437–442
Masand PS. Reply to Goldstein JM: Inaccurate information on quetiapine [letter]. Dec 687
Mason M see Reid WH
Massana J. Reboxetine versus fluoxetine: an overview of efficacy and tolerability. Suppl 14, 8–10
Masterman DL see Cummings JL
Matroos GE see van Harten PN
Mattes JA. Stroke resulting from a rapid switch from phenelzine to tranylcypromine [letter]. July 382
Mayer LES, Walsh BT. Use of selective serotonin reuptake inhibitors in eating disorders. Suppl 15, 28–34
Mazure CM see Young CR
McBride L see Bauer MS
McCullough JP see Rush AJ
McDowell DM see Levin FR
McElroy SL, Soutullo CA, Beckman DA, Taylor P Jr, Keck PE Jr. DSM-IV intermittent explosive disorder: a report of 27 cases [CME ARTICLE]. Apr 203–210
McElroy SL see Arnold LM; Keck PE Jr; Phillips KA; Soutullo CA; Strakowski SM
McEvoy JP. Introduction: new treatment options to improve clinical outcomes. Suppl 1, 3–4
McLean RYS see Smoller JW
McNamara RK see Lenox RH
Meltzer HY. Suicide in schizophrenia: risk factors and clozapine treatment. Suppl 3, 15–20
Merckelbach H see à Campo J
Meyer JM see Lauterbach EC
Miceli RJ see Hirschfeld RMA; Rush AJ
Mick E see Biederman J
Miller CH, Mohr F, Umbricht D, Woerner M, Fleischhacker WW, Lieberman JA. Prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics. Feb 69–75
Miller IW, Keitner GI, Schatzberg AF, Klein DN, Thase ME, Rush AJ, Markowitz JC, Schlager DS, Kornstein SG, Davis SM, Harrison WM, Keller MB. Treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine. Nov 608–619
Miller IW see Hirschfeld RMA
Miller MD see Zygmont M
Mirassou MM. Rectal antidepressant medication in the treatment of depression [letter]. Jan 29
Mirtazapine-Fluoxetine Study Group see Wheatley DP
Mittmann N see Lanctôt KL
Mjörndal T see Hägg S
Mohr F see Miller CH
Moleman P see Bruijn JA
Monaco CA see Tracy JI
Monahan P see Black DW
Montgomery SA. Chairman's overview: the place of reboxetine in antidepressant therapy. Suppl 14, 26–29
Montgomery SA, Schatzberg AF. Introduction. Reboxetine: a new selective antidepressant for the treatment of depression. Suppl 14, 3
Moore SD see Hertzberg MA
Morris EM see Arnold LM
Mosquera F see Gonzalez-Pinto A
Mulder PGH see Bruijn JA
Murphy DL, Andrews AM, Wichems CH, Li Q, Tohda M, Greenberg B. Brain serotonin neurotransmission: an overview and update with an emphasis on serotonin subsystem heterogeneity, multiple receptors, interactions with other neurotransmitter systems, and consequent implications for understanding the actions of serotonergic drugs. Suppl 15, 4–12
Murphy DL see Corá-Locatelli G
Murphy TK see Tueth MJ
Mutasim DF see Arnold LM
Naidu VR see Ahmed S
Nair C see Verghese C
Najavits LM see Weiss RD
Naranjo CA see Lanctôt KL
Narendran R see Zarate CA Jr
Nasrallah RA see Henderson DC
Nelson JC. Augmentation strategies with serotonergic-noradrenergic combinations. Suppl 5, 65–68
Nelson JC. Overcoming treatment resistance in depression. Suppl 16, 13–19
Nelson JC. Treatment of antidepressant nonresponders: augmentation or switch? Suppl 15, 35–41
Nemec NL see Sclar DA
Nemeroff CB. Introduction. Lithium in the treatment of manic-depressive illness: an update. Suppl 6, 3–4
Nemeroff CB see Heit S
Niehaus D see Stein DJ
Nierenberg AA, Alpert JE, Pava J, Rosenbaum JF, Fava M. Course and treatment in atypical depression. Suppl 18, 5–9
Nierenberg AA, Dougherty D, Rosenbaum JF. Dopaminergic agents and stimulants as antidepressant augmentation strategies. Suppl 5, 60–63
Nijman H see à Campo J
Nonacs R, Cohen LS. Postpartum mood disorders: diagnosis and treatment guidelines. Suppl 2, 34–40
Norman TR see Burrows GD
Nudelman E, Vinuela LM, Cohen CI. Safety in overdose of quetiapine: a case report [letter]. Aug 433
Nurcombe B. Review of Putnam FW: *Dissociation in Children and Adolescents: A Developmental Perspective*. Dec 691
Nutt DJ. Antidepressants in panic disorder: clinical and preclinical mechanisms. Suppl 8, 24–28
Nutt DJ, Bell CJ, Malizia AL. Brain mechanisms of social anxiety disorder. Suppl 17, 4–9
Nutt DJ see Ballenger JC
Nyland KE see Martinsen EW
Oh PI see Lanctôt KL
Oja G see Hägg S
Olsen T see Martinsen EW
Olson ME see Budman CL
Ono Y see Ballenger JC
Osgood-Hynes DJ, Greist JH, Marks IM, Baer L, Heneman SW, Wenzel KW, Manzo PA, Parkin JR, Spierings CJ, Dottl SL, Vitse HM. Self-administered psychotherapy for depression using a telephone-accessed computer system plus booklets: an open U.S.-U.K. study. July 358–365
Otto MW see Smoller JW
Oyffe I see Lerner AG
Panzarino PJ Jr. Costs of depression: direct and indirect; treatment versus nontreatment. Suppl 20, 11–14
Papke RL see Lenox RH
Parepally H see Ahmed S
Park KS see Budman CL
Park M see Lindenmayer J-P
Parkin JR see Osgood-Hynes DJ
Pava J see Nierenberg AA
Pedersen T see Lepola UM
Penttinen JT see Lepola UM
Perez J see Franchini L
Peskind ER. Pharmacologic approaches to cognitive deficits in Alzheimer's disease. Suppl 9, 22–27
Peterkin J see Zisook S
Peterson BS, Cohen DJ. Reply to Holmes TS: Correction [letter]. Nov 620
Peterson BS, Cohen DJ. Treatment of Tourette's syndrome: multimodal, developmental intervention. Suppl 1, 62–72
Petter T, Richter MA, Sandor P. Clinical features distinguishing patients with Tourette's syndrome and obsessive-compulsive disorder from patients with obsessive-compulsive disorder without tics. Sept 456–459
Petty RG. Management of chronic psychotic ambulatory outpatients. Suppl 19, 30–35
Phillips KA, Dwight MM, McElroy SL. Efficacy and safety of fluvoxamine in body dysmorphic disorder. Apr 165–171
Phillips KA, Gunderson CG, Mallya G, McElroy SL, Carter W. Comparison study of body dysmorphic disorder and obsessive-compulsive disorder. Nov 568–575
Phillips MI see Verghese C
Pike S see Zarate CA Jr
Pini S see Cassano GB
Pitchumoni S see Doraiswamy PM
Pliszka SR. Comorbidity of attention-deficit/hyperactivity disorder with psychiatric disorder: an overview. Suppl 7, 50–58
Pollack BG. Discontinuation symptoms and SSRIs [letter with reply]. Oct 535–536
Pollack BG see Tracy JI
Pollack MH see Smoller JW
Portera L see Goldberg JF
Potter WZ. Bipolar depression: specific treatments. Suppl 18, 30–36
Prentky RA see Kafka MP
Preskorn SH, Goldstein MG. Bupropion sustained release and smoking cessation. Suppl 4, 66–72
Prigerson HG see Zygmont M
Prince J see Biederman J
Rabins PV. Alzheimer's disease management. Suppl 13, 36–38
Rabins PV. Developing treatment guidelines for Alzheimer's disease and other dementias. Suppl 11, 17–19
Raby WN. Treatment of venlafaxine discontinuation symptoms with ondansetron [letter]. Nov 621–622
Rago WV see Gilbert DA; Rush AJ
Ramos RH, Budman CL. Emergence of koro after abrupt cessation of olanzapine. Feb 86–87
Rand EH. Priapism in a patient taking sertraline [letter]. Oct 538
Raskind MA. Clinical interface of depression and dementia. Suppl 10, 9–12
Raskind MA. Psychopharmacology of noncognitive abnormal behaviors in Alzheimer's disease. Suppl 9, 28–32
Reddy G see Bagri S
Reid WH, Keller S, Leatherman M, Mason M. ECT in Texas: 19 months of mandatory reporting. Jan 8–13
Reid WH, Mason M. Psychiatric hospital utilization in patients treated with clozapine for up to 4.5 years in a state mental health care system. April 189–194
Reoux J see Saxon AJ
Revicki D see Simon GE
Reynolds CF III see Zygmont M
Richelson E. Pharmacokinetic interactions of antidepressants. Suppl 10, 22–26
Richter MA see Petter T
Rickels K see Rudolph RL; Schweizer E
Ries R see Avery DH
Rietschel M see Lucht MJ

Roback HB. Review of Makover RB: *Treatment Planning for Psychotherapists.* June 321
Roberts DL see Feighner J
Robison LM see Sclar DA
Rochas M see Schwartz M
Rodriguez AI see Glassman AH
Roose SP. Introduction: late-life depression. Suppl 10, 3
Roose SP, Suthers KM. Antidepressant response in late-life depression. Suppl 10, 4–8
Roose SP see Barbey JT
Rosen EH. Olanzapine and negative symptoms [letter with reply]. Oct 537
Rosen RC see Ashton AK
Rosenbaum JF. Conclusion. Depression and its subtypes: a treatment update. Suppl 18, 37–38
Rosenbaum JF. Introduction. Depression and its subtypes: a treatment update. Suppl 18, 3–4
Rosenbaum JF see Cohen LS; Glazer WM; Nierenberg AA
Rothschild AJ see Byrne SE
Rouillon F, Gorwood P. Use of lithium to augment antidepressant medication. Suppl 5, 32–39
Rubin EH. Review of Pies RW: *Handbook of Essential Psychopharmacology.* Dec 691
Rucci P see Cassano GB
Rudolph RL, Fabre LF, Feighner JP, Rickels K, Entsuah R, Derivan AT. Randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. Mar 116–122
Rush AJ. Introduction: beyond SSRIs. Suppl 4, 3–4
Rush AJ, Crismon ML, Toprac MG, Trivedi MH, Rago WV, Shon S, Altshuler KZ. Consensus guidelines in the treatment of major depressive disorder. Suppl 20, 73–84
Rush AJ, Koran LM, Keller MB, Markowitz JC, Harrison WM, Miceli RJ, Fawcett JA, Gelenberg AJ, Hirschfeld RMA, Klein DN, Kocsis JH, McCullough JP, Schatzberg AF, Thase ME. Treatment of chronic depression, part 1: study design and rationale for evaluating the comparative efficacy of sertraline and imipramine as acute, crossover, continuation, and maintenance phase therapies. Nov 589–597
Rush AJ see Gilbert DA; Keller MB; Miller IW; Suppes T
Russell JM see Hirschfeld RMA; Keller MB
Russell R see Biederman J
Sachs G see Bauer MS
Saettoni M see Cassano GB
Salomon RM. Review of Miklowitz DJ, Goldstein MJ: *Bipolar Disorder: A Family-Focused Treatment Approach.* Aug 434
Sanders RD, Lehrer DS. Edema associated with addition of risperidone to valproate treatment [letter]. Dec 689–690
Sandor P see Petter T
Sansone LA see Sansone RA
Sansone RA, Wiederman MW, Sansone LA. Borderline personality symptomatology, experience of multiple types of traumas, and health care utilization among women in a primary care setting. Mar 108–111
Saran BM. Risperidone-induced tardive dyskinesia [letter]. Jan 29–30
Sax KW see Strakowski SM
Saxena S, Bystritsky A. Reply to Andrade C: Risperidone may worsen fluoxetine-treated OCD [letter]. May 256
Saxon AJ, Sloan KL, Reoux J, Haver VM. Disulfiram use in patients with abnormal liver function test results. June 313–316
Schatzberg AF. Bipolar disorder: recent issues in diagnosis and classification. Suppl 6, 5–10
Schatzberg AF. Noradrenergic versus serotonergic antidepressants: predictors of treatment response. Suppl 14, 15–18
Schatzberg AF. Reply to Pollack BG: Discontinuation symptoms and SSRIs [letter]. Oct 536–537
Schatzberg AF see Miller IW; Montgomery SA; Rush AJ
Schechter JO. Treatment of disequilibrium and nausea in the SRI discontinuation syndrome [letter]. Aug 431–432
Schein J see Honigfeld G
Schlager DS see Miller IW
Schlozman SC. Upper-extremity self-amputation and replantation: 2 case reports and a review of the literature. Dec 681–686
Schneck C. St. John's wort and hypomania [letter]. Dec 689
Schneider LS. Introduction. Alzheimer's disease: from research to practice. Suppl 11, 3
Schneider LS. New therapeutic approaches to cognitive impairment. Suppl 11, 8–13
Schooler NR see Ahmed S
Schulz SC, Findling RL, Friedman L, Kenny JT, Wise AL. Treatment and outcomes in adolescents with schizophrenia. Suppl 1, 50–54
Schwartz M, Rochas M, Weller B, Sheinkman A, Tal I, Golan D, Toubi N, Eldar I, Sharf B, Attias D. High association of anticardiolipin antibodies with psychosis. Jan 20–23
Schweizer E, Rickels K, Hassman H, Garcia-España F. Buspirone and imipramine for the treatment of major depression in the elderly. Apr 175–183
Schwenk TL, Klinkman MS, Coyne JC. Depression in the family physician's office: what the psychiatrist needs to know: the Michigan Depression Project. Suppl 20, 94–100
Sclar DA, Skaer TL, Robison LM, Galin RS, Legg RF, Nemec NL. Economic outcomes with antidepressant pharmacotherapy: a retrospective intent-to-treat analysis. Suppl 2, 13–17
Segraves RT. Antidepressant-induced sexual dysfunction. Suppl 4, 48–54
Sernyak MJ see George TP
Sethi J see Honigfeld G
Settle EC Jr. Antidepressant drugs: disturbing and potentially dangerous adverse effects. Suppl 16, 25–30
Settle EC Jr. Bupropion sustained release: side effect profile. Suppl 4, 32–36
Sforzini L see Benedetti F
Shader RI see Greenblatt DJ
Shapiro PA see Glassman AH
Sharf B see Schwartz M
Sharif ZA. Common treatment goals of antipsychotics: acute treatment. Suppl 19, 5–8
Sharma V. Venlafaxine: loss of antidepressant effect and its management [letter]. July 381–382
Shea N see Bauer MS
Shea SC. Chronological assessment of suicide events: a practical interviewing strategy for the elicitation of suicidal ideation. Suppl 20, 58–72
Shear MK, Beidel DC. Psychotherapy in the overall management strategy for social anxiety disorder. Suppl 17, 39–44
Shear MK, Clark D, Feske U. Road to recovery in panic disorder: response, remission, and relapse. Suppl 8, 4–8
Shear MK see Ballenger JC; Zygmont M
Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC. Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. Suppl 20, 22–33
Sheehan KH see Sheehan DV
Sheinkman A see Schwartz M
Shelton PS see Fertig MK
Shelton RC, Thase ME, Kowatch R, Baldessarini RJ. Update on the management of bipolar illness [CME Academic Highlights]. Sept 484–495
Sherr JD, Thaker G. Progression of abnormal involuntary movements during risperidone treatment [letter]. Sept 478–479
Shon S see Gilbert DA; Rush AJ
Siegal AP see Duncan BA
Sigal M see Lerner AG
Silvetti F see Tondo L
Simon GE. Can depression be managed appropriately in primary care? Suppl 2, 3–8
Simon GE, Heiligenstein JH, Grothaus L, Katon W, Revicki D. Should anxiety and insomnia influence antidepressant selection: a randomized comparison of fluoxetine and imipramine. Feb 49–55
Simpson GM. Introduction: routine use of atypical antipsychotic agents. Suppl 19, 3–4
Simpson GM see Lauterbach EC; Verghese C
Sjodin I see Lepola UM
Skaer TL see Sclar DA
Sledge P see Zisook S
Sloan KL see Saxon AJ
Small GW. Pathogenesis of Alzheimer's disease. Suppl 9, 7–14
Small GW, Leiter F. Neuroimaging for diagnosis of dementia. Suppl 11, 4–7
Smeraldi E see Benedetti F; Franchini L
Smith R see Lindenmayer J-P
Smoller JW, McLean RYS, Otto MW, Pollack MH. How do clinicians respond to patients who miss appointments? [CME Article] June 330–338
Soto JA see Weiss RD
Soutullo CA, McElroy SL, Keck PE Jr. Hypomania associated with mirtazapine augmentation of sertraline [letter]. June 320
Soutullo CA see McElroy SL
Spencer T, Biederman J, Wilens TE, Faraone SV. Adults with attention-deficit/hyperactivity disorder: a controversial diagnosis. Suppl 7, 59–68
Spierings CJ see Osgood-Hynes DJ
Spigset O see Hägg S
Stahl SM. Basic psychopharmacology of antidepressants, part 1: antidepressants have seven distinct mechanisms of action. Suppl 4, 5–14
Stahl SM. Basic psychopharmacology of antidepressants, part 2: estrogen as an adjunct to antidepressant treatment. Suppl 4, 15–24
Stahl SM. Brain fumes: yes, we have NO brain gas [Brainstorms]. Jan 6–7
Stahl SM. Brain tonics for brain sprouts: how neurotrophic factors fertilize neurons [Brainstorms]. Apr 149–150
Stahl SM. Getting stoned without inhaling: anandamide is the brain's natural marijuana [Brainstorms]. Nov 566–567
Stahl SM. How psychiatrists can build new therapies for impotence [Brainstorms]. Feb 47–48
Stahl SM. How to appease the appetite of psychotropic drugs [Brainstorms]. Oct 500–501

Stahl SM. Neuropharmacology of obesity: my receptors made me eat it [BRAINSTORMS]. Sept 447–448
Stahl SM. Nitric oxide physiology and pharmacology [BRAINSTORMS]. Mar 101–102
Stahl SM. Not so selective serotonin reuptake inhibitors [BRAINSTORMS]. July 343–344
Stahl SM. Recognition molecules are trailblazers for axon pathways [BRAINSTORMS]. May 215–216
Stahl SM. Selecting an antidepressant by using mechanism of action to enhance efficacy and avoid side effects. Suppl 18, 23–29
Stahl SM. Using secondary binding properties to select a not so selective serotonin reuptake inhibitor [BRAINSTORMS]. Dec 642–643
Stahl SM. What makes an antipsychotic atypical? [BRAINSTORMS] Aug 403–404
Stahl SM. When neurotrophic factors get on your nerves: therapy for neurodegenerative disorders [BRAINSTORMS]. June 277–278
Stanilla JK see Verghese C
Steffens DC see Doraiswamy PM
Stein DJ, Hawkridge S, Bouwer C, Emsley RA. Reply to Baker RW: Possible dose-response relationship for risperidone in obsessive-compulsive disorder [letter]. Mar 134
Stein DJ, Van Greunen G, Niehaus D. Can bruxism respond to serotonin reuptake inhibitors? [letter] Mar 133
Stowe ZN see Llewellyn A
Strader JR Jr see Llewellyn A
Strakowski SM, Sax KW, McElroy SL, Keck PE Jr, Hawkins JM, West SA. Course of psychiatric and substance abuse syndromes co-occurring with bipolar disorder after a first psychiatric hospitalization. Sept 465–471
Strakowski SM see Keck PE Jr
Straumanis JJ. Review of Goodnick PJ (ed): *Mania: Clinical and Research Perspectives.* Oct 539
Strong CM see Ketter TA
Su K-P see Lane H-Y
Sunderland T see Tune LE
Suppes T, Rush AJ Jr, Kraemer HC, Webb A. Treatment algorithm use to optimize management of symptomatic patients with a history of mania [CME ARTICLE]. Feb 89–96
Sussman N. Anxiolytic antidepressant augmentation. Suppl 5, 42–48
Sussman N, Joffe RT. Antidepressant augmentation: conclusions and recommendations. Suppl 5, 70–73
Sussman N, Joffe RT. Introduction: augmentation of antidepressant medication. Suppl 5, 3–4
Suthers KM see Roose SP
Tabrizi S see Doraiswamy PM
Tai I see Schwartz M
Tan C-H see Chong S-A
Targum SD see Feighner J
Tariot PN. Evaluating response to metrifonate. Suppl 9, 33–37
Tate DL see Ketter TA
Taylor P Jr see McElroy SL
Terao T, Kojima H, Eto A. Risperidone and allergic reactions [letter]. Feb 82–83
Thaker G see Sherr JD
Thase ME. Depression, sleep, and antidepressants. Suppl 4, 55–65
Thase ME. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. Oct 502–508
Thase ME, Howland RH, Friedman ES. Treating antidepressant nonresponders with augmentation strategies: an overview. Suppl 5, 5–12
Thase ME see Hirschfeld RMA; Keller MB; Miller IW; Rush AJ; Shelton RC
Thomas RM see Alexander PJ
Timmerman L see Wheatley DP
Tohda M see Murphy DL
Tohen M, Zarate CA Jr. Antipsychotic agents and bipolar disorder. Suppl 1, 38–48
Tohen M see Tondo L; Weiss RD; Zarate CA Jr
Tondo L, Baldessarini RJ, Hennen J, Floris G, Silvetti F, Tohen M. Lithium treatment and risk of suicidal behavior in bipolar disorder patients. Aug 405–414
Tonset E see Martinsen EW
Toprac MG see Gilbert DA; Rush AJ
Toren P, Laor N, Weizman A. Use of atypical neuroleptics in child and adolescent psychiatry. Dec 644–656
Toubi N see Schwartz M
Tracy JI, Monaco CA, Abraham G, Josiassen RC, Pollack BG. Relation of serum anticholinergicity to cognitive status in schizophrenia patients taking clozapine or risperidone. Apr 184–188
Trivedi MH see Rush AJ
Tronick EZ see Weinberg MK
Tueth MJ, Murphy TK, Evans DL. Special considerations: use of lithium in children, adolescents, and elderly populations. Suppl 6, 66–73
Tune LE, Sunderland T. New cholinergic therapies: treatment tools for the psychiatrist. Suppl 13, 31–35
Umbricht D see Miller CH
van den Broek WW see Bruijn JA
van der Gaag RJ see Buitelaar JK
van der Hoeven J see Buitelaar JK
Van Greunen G see Stein DJ
van Harten PN, van Trier JCAM, Horwitz EH, Matroos GE, Hoek HW. Cocaine as a risk factor for neuroleptic-induced acute dystonia. Mar 128–130
van Moffaert M see Wheatley DP
van Trier JCAM see van Harten PN
Verghese C, Abraham G, Nair C, Stanilla JK, de Leon J, Phillips MI, Simpson GM. Absence of changes in antidiuretic hormone, angiotensin II, and atrial natriuretic peptide with clozapine treatment of polydipsia-hyponatremia: 2 case reports. Aug 415–419
Verma SD, Davidoff DA, Kambhampati KK. Management of the agitated elderly patient in the nursing home: the role of the atypical antipsychotics. Suppl 19, 50–55
Vinuela LM see Nudelman E
Vitse HM see Osgood-Hynes DJ
von Moltke LL see Greenblatt DJ
Wade AG see Lepola UM
Walker EA see Katon WJ
Walsh BT see Mayer LES
Walshe TA see Bremner JD
Webb A see Suppes T
Weiden PJ, Aquila R, Emanuel M, Zygmunt A. Long-term considerations after switching antipsychotics. Suppl 19, 36–49
Weiller E see Sheehan DV
Weinberg MK, Tronick EZ. Impact of maternal psychiatric illness on infant development. Suppl 2, 53–61
Weiss RD, Greenfield SF, Najavits LM, Soto JA, Wyner D, Tohen M, Griffin ML. Medication compliance among patients with bipolar disorder and substance use disorder. Apr 172–174
Weizman A see Toren P
Weller B see Schwartz M
Wender PH. Pharmacotherapy of attention-deficit/hyperactivity disorder in adults. Suppl 7, 76–79
Wenzel KW see Osgood-Hynes DJ
West SA see Strakowski SM
Westenberg HGM. Nature of social anxiety disorder. Suppl 17, 20–24
Westenberg HGM see Ballenger JC
Wheatley DP, van Moffaert M, Timmerman L, Kremer CME, and the Mirtazapine-Fluoxetine Study Group. Mirtazapine efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe depressive disorder. June 306–312
Whitcomb SR see Daniel DG
Whitehouse PJ. Cholinergic deficit in Alzheimer's disease. Suppl 13, 19–22
Wichems CH see Murphy DL
Widlöcher DJ see Dantchev N
Wiederman MW see Sansone RA
Wilens TE see Biederman J; Spencer T
Wingard P see Bremner JD
Winkelman JW. Clinical and polysomnographic features of sleep-related eating disorder. Jan 14–19
Winsberg ME see Ketter TA
Wise AL see Schulz SC
Wiseman EJ, Henderson KL, Briggs MJ. Individualized treatment for outpatients withdrawing from alcohol. June 289–293
Woerner M see Miller CH
Wozniak J see Biederman J
Wyner D see Weiss RD
Young CR, Mazure CM. Fulminant hepatic failure from acetaminophen in an anorexic patient treated with carbamazepine [letter]. Nov 622
Young SA, Hurt PH, Benedek DM, Howard RS. Treatment of premenstrual dysphoric disorder with sertraline during the luteal phase: a randomized, double-blind, placebo-controlled crossover trial. Feb 76–80
Zametkin AJ, Liotta W. Neurobiology of attention-deficit/hyperactivity disorder. Suppl 7, 17–23
Zanardi R see Franchini L
Zarate CA Jr, Narendran R, Tohen M, Greaney JJ, Berman A, Pike S, Madrid A. Clinical predictors of acute response with olanzapine in psychotic mood disorders. Jan 24–28
Zarate CA Jr see Tohen M
Zayas EM, Grossberg GT. Treatment of psychosis in late life. Suppl 1, 5–10
Zimmer JE, Gregory RJ. Bipolar depression associated with fenfluramine and phentermine [letter]. July 383–384
Zisook S. Review of Bloom FE, Kupfer DJ (eds): *Psychopharmacology: The Fourth Generation of Progress.* Apr 201
Zisook S, Downs NS. Diagnosis and treatment of depression in late life. Suppl 4, 80–91
Zisook S, Peterkin J, Goggin KJ, Sledge P, Atkinson JH, Grant I, the HIV Neurobehavioral Research Center Group. Treatment of major depression in HIV-seropositive men. May 217–224
Zisook S see Dunner DL
Zoellner LA see Boerlin HL
Zygmont M, Prigerson HG, Houck PR, Miller MD, Shear MK, Jacobs S, Reynolds CF III. Post hoc comparison of paroxetine and nortriptyline for symptoms of traumatic grief. May 241–245
Zygmunt A see Weiden PJ